CLINICAL STUDY PROTOCOL  
NCT Number:  
Study  Title:  
Study  Number:  [STUDY_ID_REMOVED]  
A Randomized, Double -Blind, Placebo -Controlled, Phase 2 Dose 
Ranging Study to Evaluate the Efficacy and Safety of 2 Dose 
Regimens of Intravenous TAK -954 for the Prophylaxis and 
Treatment of Postoperative Gastrointestinal Dysfunction in Patients Undergoing Large - and Small- Bowel Resection
 
TAK-954-2
004
Protocol  Version  and Date:  
Version  5.0: 25-March -2021  
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
  
TAKEDA PHARMACEUTICALS
PROTOCOL
A Rando mized, Double -Blind, Pl acebo -Controlled, Phase 2 Dose Ranging Study  to Eval uate the 
Efficacy and Safet y of 2 Dose Regimens of Intravenous TAK -954 for the Prophylaxis and 
Treatment of Postoperative Gastrointestinal Dysfunct ion in Pat ients Undergoing Large -and 
Small-Bowel  Resecti on
Sponsor: Takeda Development Center Americas, Inc.
95 Hay den Avenue
Lexington, MA 02421
Study Number: TAK -954-2004
IND Number: 140120 EudraCT Number: 2018-003318-42
Compound: TAK -
954
Date: 23 March 2021 Version/Amendment 
Number:5
Amendment History :
Date Amendment Number Amendment Type Region
23 March 2021 Amendment 5 Substantial Global
09 July  2019 Amendment 4 Substantial Global
13 May  2019 Amendment 3 Substantial Local (Germany)
23 April 2019 Amendment 2 Nonsubstantial Local (Belgium)
19 December 2018 Amendment 1 Not applicable Global
15 October 2018 Initial protocol Not applicable Global
CONFIDENTIAL PROPERTY OF TAKEDA
This document is a confidential communication of Takeda. Acceptance of this document constitutes the agreement by 
the recipient that no information contained herein will be published or disclosed without written authorization from 
Takeda except to the extent necessary to obtain informed consent from thos e persons to whom the drug may be 
administered. Furthermore, the information is only meant for review and compliance by the recipient, his or her staff, 
and applicable institutional review committee and regulatory agencies to enable conduct of the study.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 2of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL1.0 ADMINISTRATIVE INFORM ATION
1.1 Contacts
A separate contact informat ion list will be provided to each site.
Takeda Development Center Americas, Inc. (TDCA) sponsored invest igators per individual 
country  requi rements will be provided wit h emergency medical contac t information cards to be 
carried by each subject.
General advice on protocol procedures should be obtained through the monitor assigned to the 
study  site. Inf ormation on service providers is given in Sect ion 3.1and relevant guidelines 
provi ded to the si te.
Contact Type/Role United States Contact European Contact
Serious adverse event and 
pregnancy reportingPRA PVS Clinical Operations:
Email: MHGSafety@prahs.com
Fax: +44 1792 525720PRA PVS Clinical Operations:
Email: MHGSafety@prahs.com
Fax: +44 1792 525720
Medical Monitor
(medical advice on protocol and 
study drug)Medical Director, Clinical Science Medical Director, Clinical Science
Responsible Medical Office r 
(carries overall responsibility 
for the conduct of the study)Medical Director, Clinical Science Medical Director, Clinical Science
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 4of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALINVESTIGATOR AGREEMENT
I confirm that I have read and that I understand this protocol, the Invest igator’s Brochure, package 
insert, and any other product information provided by the sponsor. I agree to conduct this study in 
accordance with the requirements of this protocol and also to protect the rights, safet y, privacy, 
and well -being o f study  subjects in accordance with the following:
The ethical principles that have their origin in the Declaration of Helsinki.
International Conference on Harmonisation, E6 Good Clinical Pract ice: Conso lidated 
Guideline.
All applicable laws and regulat ions, incl uding, wi thout limi tation, data privacy laws and 
regul ations.
Regulatory  requi rements for reporting serious adverse events defined in Sect ion10.2 of this 
protocol .
Terms outlined in the study  site agreement.
Responsibilit ies o f the Invest igator ( Appendix B) .
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in Appendix Dof this protocol .
Signatu re of Investigator Date
Invest igator Name (print or ty pe)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/Provi nce)
Locati on of  Facilit y (Country )
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 5of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL1.3 Protocol Amendment Summary of Changes
Protocol Amendment 5 Summary and Rationale:
This sect ion describes the changes in reference to the protocol incorporating Amendment 5. 
The primary  reason for thi s amendment is to maint ain subject safet y and study  integrity and 
provi de flexibilit y to study  parti cipants in the context of the global coronavi rus disease 2019 
(COVID -19) pandemic as permitted by local regulations. Study  modificat ions to mit igate the 
impact of COVID -19 include the addit ion of Exclusion Criterion 15 for subjects with known 
COVID -19 infection, the addit ion of flexibilit y inprocedures and the expansio n of the durat ion of 
the screening period (including potential screening of subjects on the day  of surgery ), the 
allowance for a follow -up visit 14 days after the last dose to be performed via a phone call, the 
inclusio n of COVI D-19 as a reason for subject discontinuat ion from the study , and the allowance 
of electroni c signature on the informed consent form if approved by  the si te insti tutional review 
boards/ethics committees.
Protocol  Amendment 5 includes the addit ion of inclusi on and exclusio n criteria related to the 
American Societ y of Anesthesio logists (ASA) physical status classificat ion and severe 
comorbidi ties to not enroll subjects with high risk of surgery .
This amendment also provides addit ional inform ation fro m the upda ted Invest igator’s Brochure 
Edition 5 (13 April 2020) that clarified mean TAK -954 exposure, added completed TAK -954 
studi es, and provi ded addi tional inform ation concerning the benefit -risk profile (Section 4.3
Benefit -Risk Profile )
.
In addit ion, this amendment clarifies the inclusio n/exclusio n criteria, changes to study assessments, 
and clarifies or modifies study  procedures: rem oval of glucose -dependent insulinotropic peptide 
(GIP) and DNA blood sampling; adjust ment of the number of and co llection time windows of 
pharmacokinet ic (PK) samples; a djust ment of timing and number of electrocardiogram (ECG) 
procedures; and defined t ime assessment windows for the Day 14 visit, ECG procedures, and 
biomarker sampling.
Notably, just before this amendment, the planned interim analysis (IA) was conducted in 
accordance with the protocol to allow the internal mo nitoring co mmittee (IMC) to review the 
safet y and efficacy data. The IMC recommended the discont inuat ion of 2 active treatment arms, 
and Amendment 5 does update some of the language around dosing arms to reflect that change. 
Addit ionally, a revised sample size is provided for the remaining 3 treatment arms based on 
blinded assessments that were conducted using efficacy  assumpt ions of the original protocol 
before the IA to mit igate the statist ical, clinic al, and operational risks to this study  due to 
COVID -19 pandemic (ie, not result ing fro m the IA and data monitoring committee review o f IA).
In thi s amendment, minor grammat ical, editorial, formatting, and administrative changes not 
affect ing the conduct o f the study  are included for clarification and administrative purposes only.
Administrative changes incorporated in this amendment include changing the sponsor fro m 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 16of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALTABLE OF CONTENTS
1.0 ADMINISTRATIVE INFOR MATION ........................................................................... 2
1.1 Contacts ..................................................................................................................... 2
1.2 Approval .................................................................................................................... 3
1.3 Protocol  Amendment Summary o f Changes ............................................................... 5
2.0 STUDY SUMMARY .................................................................................................... 21
3.0 STUDY REFERENCE INFO RMATION ...................................................................... 27
3.1 Study -Related Responsibilit ies................................................................................. 27
3.2 Principal Invest igator/Coordinating Invest igator ...................................................... 27
3.3 List of Abbreviat ions............................................................................................... 28
3.4 Corporate Identificat ion........................................................................................... 29
4.0 INTRODUCTION ......................................................................................................... 30
4.1 Background ............................................................................................................. 30
4.2 Rationale for the Proposed Study ............................................................................. 31
4.3 Benefit -Risk Profile .................................................................................................33
5.0 STUDY OBJECTIVES AND ENDPOINTS .................................................................. 34
5.1 Object ives................................................................................................................ 34
5.1.1 Primary Obje ctive(s) ........................................................................................ 34
5.1.2 Secondary  Object ives...................................................................................... 34
5.1.3 Exploratory  Objectives .................................................................................... 34
5.2 Endpoints ................................................................................................................. 35
5.2.1 Primary Endpo int............................................................................................. 35
5.2.2 Seco ndary  Endpo ints....................................................................................... 35
5.2.3 Safety Endpo ints.............................................................................................. 35
5.2.4 Exploratory  Endpo ints..................................................................................... 36
6.0 STUDY DESIGN AND DES CRIPTION ....................................................................... 36
6.1 Study  Design ........................................................................................................... 36
6.2 Justificatio n for Study  Desi gn, Dose, and Endpoints ................................................ 40
6.3 End of the Study ...................................................................................................... 41
6.4 Prem ature Terminat ion or Suspension o f Study  or Study  Site................................... 42
6.4.1 Criteria for Premature Terminat ion or Suspension of the Study ........................ 42
6.4.2 Criteria for Premature Terminat ion or Suspension of Study  Sites..................... 42
6.4.3 Procedures for Prema ture Terminati on or Suspension of the Study  or the 
Parti cipation of  Study  Site(s) ........................................................................... 42
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 17of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS .............. 42
7.1 Inclusio n Cri teria..................................................................................................... 42
7.2 Exclusio n Cri teria.................................................................................................... 43
7.3 Exclud ed Medicat ions.............................................................................................. 44
7.4 Criteria for Di scontinuati on or Wi thdrawal  of a Subject ........................................... 45
7.5 Procedures for Discont inuat ion or Withdrawal o f a Subject ...................................... 46
8.0 CLINICAL STUDY MATER IAL MANAGEMENT ..................................................... 46
8.1 Study  Drug and Materials ........................................................................................ 46
8.1.1 Dosage Form, Manufacturing, Packaging, and Labeling .................................. 46
8.1.1.1 TAK -954 .................................................................................................46
8.1.1.2 Ancillary  Materi als.................................................................................. 47
8.1.2 Storage ............................................................................................................ 47
8.1.3 Dose and Regim en........................................................................................... 47
8.1.4 Overdose ......................................................................................................... 48
8.2 Study  Drug Assignment and Dispensing Procedures ................................................ 49
8.3 Randomization Code Creation and Storage .............................................................. 49
8.4 Study  Drug Blind Maintenance ................................................................................ 50
8.5 Unblinding Procedure .............................................................................................. 50
8.6 Acco untabilit y and Destruction of Sponsor -Supplied Drugs ..................................... 50
9.0 STUDY PLAN .............................................................................................................. 52
9.1 Study  Procedures ..................................................................................................... 52
9.1.1 Inform ed Consent Procedure ............................................................................ 52
9.1.2 Dem ographics, Medi cal History , and Medicat ion History  Procedure ................ 52
9.1.3 Physical Examinat ion Procedure (Including Neurology  Examinat ion).............. 52
9.1.4 Weight, Height, and BMI ................................................................................. 53
9.1.5 Vital Sign Procedure ........................................................................................ 53
9.1.6 Primary Efficacy  Measurement ........................................................................ 53
9.1.7 Study  Surgery .................................................................................................. 54
9.1.8 Clinic al Assessments ....................................................................................... 54
9.1.9 Docum entati on of  Concurrent Medi cal Procedures .......................................... 55
9.1.10 Docum entati on of  Conco mitant Medi cations ................................................... 55
9.1.11 Docum entati on of  Core ERP ............................................................................ 55
9.1.12 Procedures for Clinical Laboratory  Samples .................................................... 55
9.1.13 Contraception and Pregnancy Avo idance Procedure ........................................ 56
9.1.14 Pregnancy ........................................................................................................ 57
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 18of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL9.1.15 ECG Procedure ................................................................................................ 58
9.1.16 Biomarker Sam ple Collect ion.......................................................................... 59
9.1.17 PK Sam ple Collect ion...................................................................................... 59
9.1.17.1 Collect ion of Plasma for PK Sampling ..................................................... 59
9.1.18 Primary Specimen Collection ........................................................................... 60
9.1.19 Docum entati on of  Screen Failure ..................................................................... 60
9.1.20 Docum entati on of  Rando mization .................................................................... 60
9.1.21 Qualit y of Life Assessment .............................................................................. 61
9.2 Schedule of Observat ions and Procedures ................................................................ 61
9.2.1 Post Study  Care ............................................................................................... 61
10.0 PRETREATMENT EVENTS AND ADVERSE EVE NTS ............................................ 61
10.1 Definit ions............................................................................................................... 61
10.1.1 Pretreatment SAEs ........................................................................................... 61
10.1.2 AEs ................................................................................................................. 61
10.1.3 Addit ional Po ints to Consider for AEs ............................................................. 61
10.1.4 SAEs ............................................................................................................... 63
10.1.5 Severit y of AEs ................................................................................................ 64
10.1.6 Management of Specific AEs ........................................................................... 64
10.1.6.1 CV Disorders ........................................................................................... 64
10.1.6.2 Serotonin Syndrome ................................................................................ 66
10.1.6.3 Diarrhea ................................................................................................... 67
10.1.6.4 Abnorm al Liver Tests .............................................................................. 67
10.1.6.5 AESI ....................................................................................................... 67
10.1.7 Causalit y of AEs.............................................................................................. 68
10.1.8 Relationship to Study  Procedures ..................................................................... 68
10.1.9 Start Date ......................................................................................................... 68
10.1.10 Stop Date ......................................................................................................... 68
10.1.11 Frequency ........................................................................................................ 68
10.1.12 Action Concerning Study  Drug ........................................................................ 69
10.1.13 Outcom e.......................................................................................................... 69
10.2 Procedures ............................................................................................................... 69
10.2.1 Collect ion and Reporti ng of AEs ..................................................................... 69
10.2.1.1 AE Collection Period ............................................................................... 69
10.2.1.2 AE Reporting ........................................................................................... 70
10.2.1.3 AESI ....................................................................................................... 70
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 19of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL10.2.2 Collect ion and Reporti ng of SAEs ................................................................... 70
10.3 Follow-up of  SAEs .................................................................................................. 71
10.3.1 Safety Reporting to Invest igators, IRBs or IECs, and Regulatory  Authori ties...71
11.0 STUDY -SPECIFIC COMMITTEES ............................................................................. 71
11.1 Independent CEC ..................................................................................................... 71
11.2 Internal Monitoring Committee ................................................................................ 72
12.0 DAT A HANDLING AND RE CORDKEEPING ............................................................ 72
12.1 CRFs (El ectronic and Paper) .................................................................................... 72
12.2 Record Retention ..................................................................................................... 73
13.0 STATIST ICAL METHODS .......................................................................................... 73
13.1 Statistical and Analyt ical Plans ................................................................................ 73
13.1.1 Analysis Sets ................................................................................................... 74
13.1.2 Analysis of Demographics and Other Baseline Characterist ics......................... 74
13.1.3 Efficacy Analysis ............................................................................................. 74
13.1.4 PK Analysis ..................................................................................................... 75
13.1.5 Safety Analysis ................................................................................................ 75
13.2 IA and Criteria for Early Terminat ion...................................................................... 75
13.3 Determinat ion of Sample Size .................................................................................. 76
14.0 QUALITY CONTROL AND QUALITY ASSURANCE ............................................... 76
14.1 Study -Site Moni toring Visit s................................................................................... 76
14.2 Protocol  Deviat ions.................................................................................................. 77
14.3 Qualit y Assurance Audits and Regulatory  Agency  Inspect ions................................ 77
15.0 ETHICAL ASPECTS OF T HE STUDY ........................................................................ 77
15.1 IRB and/or IEC Approval ........................................................................................ 77
15.2 Subject Informat ion, Inform ed Consent, and Subject Authorizat ion......................... 78
15.3 Subject Confidentialit y............................................................................................ 79
15.4 Publicat ion, Di sclosure, and Clinical Trial Registration Policy .................................80
15.4.1 Publicat ion and Disclosure ............................................................................... 80
15.4.2 Clinical Trial Registration ................................................................................ 80
15.4.3 Clinical Trial Result s Disclosure ...................................................................... 80
15.5 Insurance and Co mpensation for Injury .................................................................... 81
16.0 REFERENCES .............................................................................................................. 81
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 20of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALLIST OF IN -TEXT TABLES
Table 8.a Dose and Regimen Prior to Protocol Amendment 5 ............................................ 48
Table 8.b Dose and Regimen as a Result of Protocol Amendment 5 ................................... 48
Table 9.a Clinical Laboratory  Tests ................................................................................... 56
Table 9.b Primary Specimen Collection ............................................................................. 60
Table 10.a NCI CTCAE ...................................................................................................... 64
Table 10.b Management of QT Prolongat ion by NCI CTCAE Grade ................................... 65
Table 10.c Management of SVT by  NCI CTCAE Grade ...................................................... 66
LIST OF IN-TEXT FIGURES
Figure 6.a Schemat ic of Study  Design Pri or to Protocol  Amendment 5 ............................... 38
Figure 6.b Schemat ic of Study  Design By  Protocol  Amendment 5 ...................................... 39
Figure 9.a Num erical  Rating Scale ...................................................................................... 54
LIST OF APPENDICES
Appendix A Schedule of Study  Procedures ............................................................................ 83
Appendix B Responsibilit ies o f the Invest igator ..................................................................... 87
Appendix C Elements of the Subject Informed Consent ......................................................... 89
Appendix D Invest igator Consent to Use of Personal Informat ion.......................................... 92
Appendix E Protocol  History.................................................................................................93
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 21of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL2.0 STUDY SUMMARY
Name of Sponsor(s):
Takeda Development Center Americas, Inc. Compound:
TAK -954
Title of Protocol: A Randomized, Double -Blind, 
Placebo -Controlled, Phase 2 Dose Ranging Study to 
Evaluate the Efficacy and Safety of 2 Dose Regimens of 
Intravenous TAK -954 for the Prophylaxis and Treatment of 
Postoperative Gastrointestinal Dysfunction in Patients 
Undergoing Large -and Small -Bowel ResectionIND No.: 140120 EudraCT No.:
2018 -003318 -42
Study Number: 2004 Phase: 2b
Study Design:
This phase 2, randomized, placebo -controlled, parallel 5 -group, double -blind study is designed to determine: (1) if 
TAK -954 decreases the duration of gastrointestinal (GI) dysfunction in patients undergoing major abdominal open or 
laparoscopic -assisted surgeries that involve significant bowel manipulation, (2) w hether preoperative dosing alone or 
a preoperative and postoperative dosing regimen is the most effective dosing regimen to decrease the duration of 
postoperative GI dysfunction (POGD) and improve clinical outcomes, and (3) the most appropriate dose and dosing 
regimen to advance into phase 3.
Subjects will be randomized in a 1:1:1 :1:1 ratio into 1 of 5 parallel treatment groups:
Regimen 1: Placebo (normal saline 100 mL infusion over 60 minutes) preoperation and daily postoperation until 
return of upper and lower GI function (ie, resolution of POGD) or for up to 10 days.
Regimen 2: TAK -954 (0.1 mg/100 mL infusion over 60 minutes) preoperation and daily postoperation until 
return of upper and lower GI function or for up to 10 days.
Regimen 3: TAK -954 (0.5 mg/100 mL infusion over 60 minutes) preoperation and daily postoperation until 
return of upper and lower GI function or for up to 10 days.
Regimen 4: TAK -954 (0.1 mg/100 mL infusion over 60 minutes) preoperation and daily placebo infusions 
postoperation until return of upper and lower GI function or for up to 10 days.
Regimen 5: TAK -954 (0.5 mg/100 mL infusion over 60 minutes) preoperation and daily placebo infusions 
postoperation until return of upper and lower GI function or for up to 10 days.
Subject randomization will be stratified by laparoscopic and open surgery procedures.
Follo wing an interim analysis (IA) specified in Protocol Amendment 4, 2 of the above TAK -954 regimens are 
discontinued based on internal monitoring committee (IMC) recommendations. As a result, eligible subjects will be 
equally  randomized to into 1 of 3 the rem aining parallel treatment groups:
Regimen 1: Placebo (normal saline 100 mL infusion over 60 minutes) preoperation and daily postoperation until 
return of upper and lower GI function (ie, resolution of POGD) or for up to 10 days.
Regimen 3: TAK -954 (0.5 mg/ 100 mL infusion over 60 minutes) preoperation and daily postoperation until 
return of upper and lower GI function or for up to 10 days.
Regimen 5: TAK -954 (0.5 mg/100 mL infusion over 60 minutes) preoperation and daily placebo infusions 
postoperation until return of upper and lower GI function or for up to 10 days.
It is standard of practice for the postoperative care of patients after colorectal surgery to implement an enhanced 
recover y pathway (ERP) to reduce the time to recover y of GI function (motility) . To provide a consistent ERP as 
baseline therapy for all subjects, they will receive the same core features of an ERP for postoperative care as outlined 
below:
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 22of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALCore ERPs:
Minimize opioid use while maintaining adequate pain control through use of multimodal analgesia. Suggested 
analgesics include opioid alternatives such as nonsteroidal anti -inflammatory drugs (eg, ketorolac tromethamine 
IV), acetaminophen (paracetamol), or oral pregabalin when possible. It is recommended that at least 2 different 
analgesics with different mechanism of action are tried and failed before prescribing opioids. 
Maintenance of euvolemia and normal salt and electrolyte state in perioperative perio d.
No routine use of prophylactic nasogastric (NG) tubes postsurgery. NG tubes should only be used if there is a 
documented medical reason to justify them.
Use of a standardized risk -based strategy for postoperative nausea and vomiting (PONV) prophylaxis: use of 
preoperative antiemetic prophylaxis in patients with 1 or more risk factors of the simplified Apfel Score (female 
gender, planned postoperative use of opioids, nonsmokers, history of PONV/motion sickness).
Early  oral feeding postsurgery when possibl e. Clear liquids after the surgery on Day 1, advancing to soft diet on 
Day 2 if tolerant to liquids (no nausea or vomiting). 
Early  mobilizatio n starting after the surgery on Day 1 when possible.
Criteria for resolution of upper and lower GI function is ti me to first tolerance of solid food (defined as no vomiting or 
no clinically significant nausea for 1 calendar day after a solid meal) and time to first spontaneous bowel movement, 
whichever occurs later, up to Day 10 postsurgery. 
Following hospital discharge, subjects will be instructed to contact their physician if they have recurring symptoms 
suggestive of POGD to evaluate the need for hospital readmission in case of relapse. All subjects will return to clinic 
for a follow -up visit 14 days (±4 days) pos t last dose; however, during the coronavirus disease 2019 (COVID -19) 
public health emergency, the follow -up visit 14 days post last dose may be conducted via phone call (eg, collection of 
AEs, concomitant medications, and monitoring) to extend flexibility to study subjects. In the case of a phone call 
follow -up, phy sical examination (including neurology examination), vital signs, or pregnancy test would not be 
collected; however, AEs will be assessed, including a safety check on any emerging clinical signs or symptoms. 
Subjects may be requested to return to the site for further safety assessment due to reported AEs at the investigator’s 
discretio n. The ty pe of visit (whether clinic visit or phone call) must be recorded in the study records. Quality of life 
assessments will be completed by the subject in their home on the same day as the safety follow -up call and completed 
questionnaires will be mailed to the clinic. Subjects will be contacted by phone 30 (±3 days) and 90 days (±7 days) 
posttreatment for a saf ety follow -up.
Two preplanned IAs will be conducted when a priori enrollment goals have been achieved. Bayesian approach will be 
applied after these IAs for decision making for potential study modification including futility, dose and dosing 
regimen decisi on, and sample size adjustment. In case dose modification is needed after the IA, the maximal dose for 
potential modification of doses/regimens will be 1.0 mg. The duration of drug administration (up to 10 days 
postsurgery) will not be changed. By this pro tocol amendment, the second IA is removed from the protocol.
Primary Objectives:
To assess the efficacy and safety of intravenous (IV) TAK -954 for accelerating the recover y of GI function 
postsurgery in patients undergoing open or laparoscopic -assisted pa rtial small -or large -bowel resection.
Secondary Objectives:
To determine efficacy and safety of preoperative dosing of IV TAK -954 relative to preoperative and 
postoperative regimens of up to 10 days of IV TAK -954 for accelerating the recovery of GI functio n postsurgery.
To determine the relative efficacy and safety of 0.1 mg and 0.5 mg IV TAK -954 given either preoperatively alone 
or preoperatively and postoperatively compared with placebo of up to 10 days or resolution of GI dysfunction 
postsurgery f or accelerating the recovery of GI function postsurgery. 
To determine the pharmacokinetics (PK) of TAK -954 in patients undergoing major abdominal surgery.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 23of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALSubject Population: Patients undergoing elective open or laparoscopic -assisted partial small —or large—bowel 
resection.
Number of Subjects:
The planned total sample size prior to Protocol Amendment 
5 is approximately 200 to 375 subjects:
TAK -954 0.1 mg/100 mL preoperative and daily: 
minimum of 25 and up to a maximum of 100 subjects.
TAK -954 0.1 mg/100 mL preoperative only: minimum 
of 25 and up to a maximum of 100 subjects.
TAK -954 0.5 mg/100 mL preoperative and daily: 
minimum of 25 and up to a maximum of 100 subjects.
TAK -954 0.5 mg/100 mL preoperative only: minimum 
of 25 and up to a maximum of 100 subjects.
Placebo: 100 subjects preoperatively and daily.
With this Protocol Amendment 5, the planned total sample 
size is approximately 180 subjects:
Enroll additional subjects to reach overall total of 
50subjects/remaining treatment groups (actually 
accumu lated sample size at IA plus the number of 
additional subjects to be enrolled after the IA) for the study: 
TAK -954 0.5 mg/100 mL preoperative and daily: 
minimum overall total of approximately 50 subjects.
TAK -954 0.5 mg/100 mL preoperative only: minimum 
overall total of approximately 50 subjects.
Placebo: overall total of approximately 50 subjects 
preoperatively and daily.Number of Sites: 
Estimated total: approximately 30 in North America 
and Europe. 
Dose Levels:
Prior to Protocol Amendment 5: TAK -954 0.1 and 0.5 mg
Placebo
By Protocol Amendment 5: TAK -954 0.5 mg
PlaceboRoute of Administration:
TAK -954 IV
Placebo IV
Duration of Treatment:
Resolution of postoperative GI function or 10 days.Period of Evaluation:
Up to 10 -day treatment period; 14 -day ob servation 
period post last dose for recurrence of symptoms 
(inpatient or outpatient); safety follow -up 
14(±4days), 30 (±3 days), and 90 days (±7 days) post 
last dose.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 24of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALMain Criteria for Inclusion:
Subject eligibility is determined according to the following criteria before entry into the study:
The subject is male or female (and not pregnant) and is at least 18 years old.
The subject is scheduled to undergo a laparoscopic -assisted, or open partial small -or large -bowel, resection.
The subject’s American Society of Anesthesiologists (ASA) physical status classification is ASA 1 to 3.
A female subject of childbearing potential willing and agreeable to use highly effective contraception or sexual 
abstinence during the course of the study and up to 3 0-days posttreatment.
Main Criteria for Exclusion:
Any subject who meets any of the following criteria will not qualify for entry into the study:
Has significant mechanical bowel obstruction that is not expected to resolve after the surgery, short bowel 
syndrome, pre -existing clinically significant GI motility disorder (eg, gastroparesis, scleroderma, chronic 
intestinal pseudo -obstruction), uncontrolled diabetes (glycosylated hemoglobin [HbA1c] >10%), has an active 
gastric pacemaker, or requires parenteral nutrition.
Previous major abdominal surgery (eg, gastrectomy, gastric bypass, gastric sleeve, lap banding, Whipple, 
pancreatic resection, total/subtotal colectomy, hemicolectomy, extensive bowel resection). 
Histor y of radiation therapy to the abdomen or pelvis.
Scheduled to undergo any of the following surgeries: low anterior resection, total or subtotal colectomy, 
colostomy, ileostomy, or reversal of stoma, or has a diagnosis that requires rectal resection (eg, tumors in the 
anorectum) and will likely re quire lower anterior resection surgery. Subjects with planned surgery for which there 
is no anticipated significant rectal resection and is, therefore, likely to preserve anorectal function and continence 
postsurgery, will likely be eligible for inclusion in the study if they meet all the study inclusion/exclusion criteria 
(eg, subjects with lesions not involving the rectum [sigmoid colon and above]).
Has pre -existing hepatic disease that meets Child -Pugh Class B (moderate; total score 7 to 9 points) or C ( severe; 
total score 10 to 15 points).
Has alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >3 ×upper limit of normal 
(ULN), or total bilirubin >2 ×ULN.
Has an estimated glomerular filtration rate <30 mL/min.
Has received alvimopan, erythromy cin, prucalopride, metoclopramide, domperidone, cisapride, mosapride, 
renzapride, o r azithromy cin in the 24 hours prior to starting study drug.
Has a resting heart rate of <50 beats per minute (bpm).
Has clinically significant electrocardiogram (E CG) abnormalities indicative of cardiac conduction abnormality or 
acute cardiac instability as determined by the investigator at screening; more than first degree atrioventricular 
(AV) block; >5 beats of nonsustained ventricular tachycardia (VT) at a rate >120 bpm; or ECG changes 
consistent with acute myocardial ischemia or infarction. 
Has a QT interval with Fridericia correction method (QTcF) interval ≥450 msec or other factors that increase the 
risk of QT prolongation or arrhythmic events at screening. T he records of subjects with bundle branch block and 
a prolonged QTcF should be reviewed by a medically qualified person in consultation with the medical monitor 
and the sponsor for potential inclusion.
Had acute myocardial infarction or ischemia within the past 12 months. Subjects with increased cardiac risks for 
surgery  including coronary artery disease or prior myocardial infarction and evidence of reduced left ventricular 
function or history of angina should be assessed by the investigator for stability and control of their cardiac 
conditio n and risk of surgery, and excluded if in the investigator’s opinion, participation in the study is not 
considered appropriate. The sponsor should be consulted if subjects with these conditions are considered by the 
investigator to be acceptable.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 25of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALHad pulmonary embolism, deep venous thrombosis, or mechanical ventilation for any medical condition within 
the past 12 months. Subjects with a history of multiple venous thrombosis or pulmonary embolic events, history 
of a hy percoagulable condition, history of severe exacerbation for chronic obstructive pulmonary disease or 
evidence of pulmonary hypertension should be assessed by the investigator for stability and control of their 
conditio ns and risk of surgery, and excluded if i n the investigator’s opinion, participation in the study is not 
considered appropriate. The sponsor should be consulted if subjects with these conditions are considered by the 
investigator to be acceptable.
Scheduled for abdominal surgery that is classifie d as emergency.
Main Criteria for Evaluation and Analyses:
The primary efficacy endpoint for this study is time from the end of surgery to resolution of upper and lower GI 
function (ie, time to tolerance of solid food [defined as first occurrence of no vo miting or no clinically significant 
nausea for 1 calendar day after a solid meal] and time to first spontaneous bowel movement, whichever occurs later) 
up to Day 10 postsurgery. 
Secondary endpoints for this study are:
Time from the end of the surgery (tim e the incision is closed) until ready for discharge (defined as the time until 
the subject presents effective intestinal transit [spontaneous bowel movement], tolerates solids without vomiting 
or clinically significant nausea for 1 calendar day after a sol id meal, has satisfactory pain control with oral 
analgesics, and is medically stable/free of complications).
Time from the end of surgery until the discharge order is written.
Time from the end of the surgery to discharge from hospital.
Time from end of su rgery  to tolerance of solid food (defined as first occurrence of intake of solids without 
vomiting or clinically significant nausea for 1 calendar day after a solid meal) up to Day 10 postsurgery.
Time from end of surgery to first spontaneous bowel movemen t (defined as a stool not induced by the use of 
enemas or laxatives) up to Day 10 postsurgery.
Percent of subjects with POGD ≥5 days, defined as subjects unable to tolerate solid foods, take anything by 
mouth, or requiring insertion or reinsertion of NG at or after 5 days postsurgery.
Percentage of subjects requiring insertion of NG tube postsurgery, for drainage and symptom relief in case of 
persistent nausea and vomiting postsurgery up to Day  24 postsurgery (up to 10 -day treatment period plus 14 -day 
obser vation period post last dose for recurrence of symptoms).
Time from end of surgery to first flatus up to Day 10 postsurgery.
Observed plasma concentration of TAK -954 at the end of infusion on Day 1.
Statistical Considerations:
The full analysis set (FAS) will include all subjects who were randomized and received at least 1 dose of study drug 
and have at least 1 postbaseline value for assessment of efficacy. In FAS, subjects will be analyzed by the treatment to 
which they were randomized.
The per -protocol s et (PPS) will include all FAS subjects who had no major protocol deviation that could confound the 
interpretation of the primary analyses based on the FAS. The major protocol deviations that lead to a subject’s 
exclusion from the FAS to form the PPS will b e specified in the statistical analysis plan. The PPS will be used to 
perform sensitivity analysis for the efficacy endpoints.
The safety analysis set (SAF) will include all subjects who were randomized and received at least 1 dose of 
double -blind study  drug. In SAF, subjects will be analyzed according to the treatment they received. 
In the final analy ses of efficacy endpoints, for the 2 discontinued treatment arms, only the summary statistics (n, mean, 
SD, median, minimum, and maximum for continuous endpo ints; number and percentage of subjects for categorical 
data; the number and percentages of events and censoring, median, minimum, and maximum for time to event 
endpoint) will be provided; for the remaining treatment groups after IA, the inferential statis tics (point estimates of 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 26of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALinterest and 90% CIs and 1 -sided p -values) for each treatment group and the TAK -954 doses/regimens in comparison 
with placebo will be provide along with summary statistics.
Primary  Efficacy Analysis : The primary  endpoint will be analyzed using the Cox proportional hazard model with 
treatment group as a single covariate, with Efron’s method of tie handling, stratified by randomization stratification 
factor. Hazard ratios between TAK -954 doses/regimens and placebo and their 90% CIs ba sed on the Cox model will 
be presented. P -values for the comparisons of TAK -954 doses/regimens and placebo will be calculated using Wald 
chi-square test based on the Cox model and presented. Median time to resolution of upper and lower GI function will 
be estimated by Kaplan -Meier survival analysis. The hazard ratios and median time differences between TAK -954 
doses/regimens and placebo will be used to express the magnitude of treatment effects. The statistical tests will be 
1-sided comparing TAK - 954 doses/ regimens to placebo. As a sensitivity analysis, the primary endpoint will be 
analy zed using the same method above based on PPS.
Secondary Efficacy Analysis : The secondary endpoints time to tolerance of solid food from the end of surgery, time to 
first spo ntaneous bowel movement from the end of surgery, time from the end of surgery until ready for discharge, 
time from the end of surgery until the discharge order is written, time from the end of surgery to discharge from 
hospital, and time from the end of sur gery to first flatus will be analyzed using similar statistical methods described for 
the primary efficacy analysis.
The comparisons of TAK -954 dose levels and placebo in percent of subjects with POGD ≥5 days and the percent of 
subjects requiring insertion of NG tube postsurgery will be based on the Miettinen and Nurminen’s method stratified 
by randomization stratification factor for risk difference.
Sample Size Justification:
Assuming 80% of subjects will have resolution of POGD at the end of study in th e placebo group and 92.5% of 
subjects will have resolution of POGD at the end of study in the active TAK -954 doses, a total of approximately 300 
subjects (100 per treatment group) will provide 80% power with a 0.05 2 -sided significance level under Protocol
Amendment 4.
In order to mitigate the statistical, clinical, and operational risks to this study in light of the COVID -19 pandemic, the 
probability of success of the study is re -estimated by blinded assessments using efficacy assumptions of Protocol 
Amend ment 4. Specifically, by the removal of the second IA per this amendment and changing the statistical 
significance level from 2 -sided 5% to 1 -sided 5%, the resulting sample size is an overall total of 50 subjects for each 
remaining arm. Under these revised assumptions and the dropping of 2 arms, an overall total of approximately 180 
subjects for the study will provide approximately 80% probability, for at least 1 remaining TAK -954 treatment arm, 
that TAK -954 is superior to placebo in time to resolution of u pper and lower GI function at a 1 -sided 5% significance 
level for the final analysis.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 27of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL3.0 STUDY REFERENCE INFO RMATION
3.1 Study -Related Responsibilities
The sponsor will perform all study -related activit ies wi th the except ion of those i dentified in the 
clinical supplier list in the study  manual . The vendors i dentified in the template for specific 
study -related activit ies will perform  these act ivities in full or in partnership with the sponsor.
3.2 Principal Investigator/Coordinating Investigator
The sponsor will sele ct a signatory  coordinat ing Investigator from the invest igators who 
participate in the study . Selection criteria for thi s investi gator will include significant knowledge 
of the study  protocol , the study  drug, thei r expertise in the therapeutic area and the conduct of 
clinical research as well as study  parti cipat ion. The si gnatory  coordinat ing invest igator will be 
requi red to revi ew and sign the clinical study  report and by doing so agrees that it accurately 
describes the results of the study .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 28of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL3.3 List of Abbrev iations
5-HT 4 5-hydroxy tryptamine receptor 4
AE adverse event
ASA American Society of Anesthesiologists
AESI adverse events of special interest
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC 24 area under the concentration -time curve from time 0 to 24 hours
AUC 24, ss area under the concentration -time curve from time 0 to 24 hours at steady state
AV atrioventricular
BfArM Bundesinstitut für Arzneimittel und Medizinprodukte
BMI body mass index
bpm beats per minute
CEC cardiovascular endpoint committee
COVID -19 coronavirus disease 2019
CRP C-reactive protein
CV cardiovascular
ECG electrocardiogram
eCRF case report form (electronic or paper)
EQ-5D EuroQol 5 -Dimensions Questionnaire
ERP enhanced recovery pathway(s)
FAS full analy sis set
FDA Food and Drug Administration
GCP Good Clinical Practice
GI gastrointestinal
GIP glucose -dependent insulinotropic peptide
HbA1c glycosylated hemoglobin
hCG human chorionic gonadotropin
IA interim analysis
ICH International Conference on Harmonisation
ID identification
IEC independent ethics committee
IL interleukin
IMC internal monitoring committee
IND Investigational Drug Application
IRB institutional review board
IRT interactive response technology
IV intravenous
LOS length of stay
MCP monocyte chemoattractant protein
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 29of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALMedDRA Medical Dictionary for Regulatory Activities
NCI CTCAE Natio nal Cancer Institute Common Terminology Criteria for Adverse Events
NG nasogastric
NOAEL no-observed -adverse -effect level
PD pharmacodynamic
PK pharmacokinetic
POI postoperative ileus
POGD postoperative GI dysfunction
PONV postoperative nausea and vomiting
PPS per-protocol set
QD once daily
QTcF QT interval with Fridericia correction method
SAE serious adverse event
SAF safety analysis set
SAP statistical analysis plan
SF-12 12-Item Short Form Health Survey
SOC standard of care
SUSAR suspected unexpected serious adverse reaction
SVT supraventricular tachycardia
VT ventricular tachycardia
Takeda Takeda Development Center Americas, Inc
ULN upper limit of normal
3.4 Corporate Identification
TDC Europe Takeda Development Centre Europe Ltd.
TDCA Takeda Development Center Americas , Inc.
TDC TDC Japan, TDC Asia, TDC Europe and/or TDCA, as applicable
Takeda TDC Japan, TDC Asia, TDC Europe and/or TDCA, as applicable
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 30of 95
Protocol Incorporating Amendment No. 5 23 March 2021
4.0 INTRODUCTION
4.1 Background
TAK -954 is a highly select ive and potent serotonin type 4 (5 -HT 4) receptor agonist that has shown 
prokinetic activ
ity throughout the gastrointestinal (GI) tract in experimental mo dels and is being 
developed for the accelerat ion of GI funct ion recovery  postsurgery .
Patients undergoing major abdo minal surgery experience a temporary, nonobstructive impairment 
of upper and l ower GI m otility (funct ion); a conditio n commo nly known as postoperative ileus 
(POI) or postoperative GI dysfunction (POGD) [1]. It is estimated that clinically significant POI 
occurs in 17% of patients undergoing major abdominal surgery [2]. The analysis of a prospective 
database of 1,461 patients undergoing surgery in a high vo lume co lorectal  surgical departm ent 
ident ified POI as 1 of the variables more likely associated with prolonged length o f stay  (LOS) in 
the hospi tal. As an average, patients developing symptomat ic GI dy sfunct ion in this study had an 
increase LOS o f 3.45 days over the expected LOS rates of 8.17 days (interquartile range 4.7 -11.9) 
for this cohort  [3].
S
igns and symptom s associated with postoperative inhibit ion of GI m otilit y include abdo minal 
d
istensi on/bloating, nausea and vo miting, lack o f bowel sounds, gas and fluid accumulat ion in the 
bowel , delayed passage of flatus o r stool, and intolerance to solid food and need for nasogastric 
(NG) tube insert ion when these symptoms occur later in the postoperative period. This 
constellation 
of signs and symptoms i s a leading cause of postsurgical co mplicat io ns and 
readmissio ns. Mult iple factors are though t to con tribute to the cause and duration of POGD: 
physical bowel manipulat io n, secretion of inflammatory mediato rs, electrolyte/fluid imbalance, 
and excessive u
se of opioid analgesics. Recen t data suggest that upregulation of inflammatory 
pathways during surgery are a m ajor facto r in the development of POI and its duration [4].
Stimulation of 5- HT 4 receptors may act ivate ant i-inflammatory and p rokinet ic mechanisms that 
prom ote earlier GI recovery , prevent, or decrease the duration of GI dysfunct ion, and facilitate 
earlier hospital discharge. Act ivation of enteric 5 -HT 4 receptors is well known to enhance motili ty 
through -out the GI tract. Postope rative administratio ns of TAK - 954 in a guinea pig model of POI 
led to a dose -dependent attenuation of the surgically -induced delay in GI transit. The potential 
prokinetic proper
ties of TAK -954 have been evaluated in a small study i n healt hy vo lunteers 
wher e the administration of single doses of TAK -954 resul ted in significant ly shorter time to first 
stool and increases in the number of stools. In addition, the results of a pilot study i n critically ill 
patients wi th  increased gastric residual vo lu mes sugges ted that a single IV dose of 0.5 mg 
consistent ly shortened gastric empt ying of a radio labeled meal as measured by scint igraphy. 
Addit ionally , 5-HT 4  agonists clinically reverse opioid -induced slowing of intestinal mot ility [ 5]. 
Results from a clinical study conducted in China suggest that postsurgical administration of a 
highly
 select ive 5 -HT 4 agonist in pat ients undergoing elect ive GI surgery was able to significantly 
decrease postsurgical recovery ti me and shorten LOS  [6].
CONFIDENTIAL
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 31of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL4.2 Ratio nale for the Proposed Study
To date, 11 clinical studies have been co mpleted:
Phase 1:
Study  0060: a single ascending oral dose study  in healt hy subjects.
Study  0061: a m ultiple ascending oral dose study  in heal thy subjects.
Study  0095: a m ultiple repeat I V dose study in healt hy subjects.
TAK -954- 1004: a 2 -period crossover drug -drug interaction study o f IV TAK - 954 with the 
oral cytochrom e P450 3A4 inhibitor, itraconazole in healt hy subjects.
TAK -954- 1005: absorption, distribut ion, metabo lism, and excret ion study  in healthy male 
subjects.
TAK -
954-1006: a single dose study  in healthy subjects and subjects with varying degrees 
of hepati c impai rment.
TAK -
954-1007: a single dose study  in healthy subjects and subjects with varying degrees 
of renal impairment.
TAK -
954-1009: phase 1, randomized, double -blind, pl acebo -controlled, single ascending 
dose (SAD), 3
-period, inco mplete block design study  in healt hy subjects.
Phase 2:
Study  0082: A phase 2a study  in subjects who were crit ically ill and were being enterally 
fed. 
TAK -954- 2002: a double -blind, double -dummy active control study  in critically ill  
subjects wi th EFI. This study  was terminated due to challenges wit h subject recruit ment.
TAK -
954-2003: a dose -ranging, rando mized, parallel, placebo -controlled study  to assess 
the effect of TAK -954 on GI and colonic transit in patients with diabetic or idiopathic 
gastroparesi s.
These studies have demonstrated acceptable PK characterist ics and no major safet y issues. This 
study  will be the first phase 2 study  to test th e efficacy  and safet y of IV TAK -954 f or accel erating 
the recovery  of GI funct ion postsurgery  in pat ients undergoing open or laparoscopic -assisted 
partial small -or large-bowel  resecti on.
Drug therapy  for the prevent ion and/or management of POI (POGD) is li
mited. Alvimopan, an 
orally  administered, peripherally act ing mu -opioid antagonist, has been approved by the Food and 
Drug Administration (FDA) for accelerating the time to upper and lower GI recovery fo llowing 
partial large -or small -bowel  resect ion with primary anastomosis. As alvimopan efficacy is related 
to opi oid administrati on, its usefulness may become limited wit h the increasing practice of 
limit ing opio id use during and postsurgery. Alvimopan prescribing is restricted to inst itutions and 
physicians with specific training (Risk Evaluat ion and Mit igation Strategy ) and for short -term use 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 32of 95
Protocol Incorporating Amendment No. 5 23 March 2021
(up to 7 days for a maximum of 15 doses) due to association of higher incidence of cardiac events 
upon long -term  use. Init iatives aimed at reducing LOS, including the expanded use of laparoscopic 
colorectal 
surgery and enhanced recovery pathways (ERP), have been adopted by m any h ospitals 
and surgical services. ERP standardize perioperative care to facilit ate “fast track” recovery . ERPs 
(including but not limited to  early withdrawal  of NG sucti on, early am bulat io n and provi sion of 
liquid (Day 1) and solid foods (Day 2), as well decreased opio id use) have had modest success in 
decreasing the duration of POI (1 -2 days’ decrease in LOS after colorectal surgery ) [7]. Despite 
compliance wit h ERP and refined discharge cr
iteria, some pat ients fail early discharge leading to a 
disproporti onate use of healt hcare resources. Data fro m a retrospective review of a prospectively  
maintained departmental database of pat ients at Universit y Hospi tals-Case Medical  center 
suggested that approximately half of the patients undergo ing majo r laparoscopi c col onic surgery  
have a delayed discharge time (>4 days) despite the implementation of standardized  early recover y 
plans. Patients with delayed discharge were significant ly mo re likely to present with postoperative 
complicat io
ns, 30 -day reoperati on rates and dire ct hospi tal cost. Ri sk factors associated with 
delayed discharge in  this study include lower body mass index (BMI), comorbidit y, acet ylsalicylic 
acid use, prolonged surgi cal  times, increased blood loss during surgery [8]. The significant risk of 
delayed postoperative recovery  despi te enh anced recovery  after surgery i mplementation was also 
highlighted in another recent study that ev aluated the incidence of prolonged POI (defined as the 
need for NG tube reinsert ion) in patients undergo ing co lorectal  surgery  in a single site cente r in 
Switzerl
and. In this study, up to 24.7% of patients needed postoperative reinsertion of NG tube at 
the 3.9 ± 2.9 postoperative day [9]. All these data reinforce the need of additional pharmacological 
measures aimed at prevent ing POGD as this is the postoperative co mplicat io n most likely related 
to prol onged length of hospital stay .
Manipulation of the 
intestines induces an inflamma tory response [4]. In a guinea p ig model of POI, 
preope rative administration  of a 5- HT 4  agonist was reported to significant ly accelerate and restore 
delayed upper and lo wer GI transit [10]. Stimulat ion of 5- HT 4 receptors increases vagal efferent 
activit y resul ting in activation o f nicotinic alpha 7 acetylcho line receptors and inhibit ion of 
resident m acrophage and splenic lymphocy te rel ease of inflammatory mediators (eg, tumor 
necrosis factor -alpha) [ 11] . 
Rationale for Biomarker Evaluation
Increased levels o f circulat ing inflammatory m arkers like interl eukin (IL) -6, IL -10, monocyte 
chemoattractant protein (MCP) -1, high-sensi tiv ity C -reactive protein (CRP), and alarmins like 
S100A8 and S100A12 fo llowing surgery have been associ ated wi th slower recovery and a l onger 
stay
 in the intensive care unit [12]. In this study, inflammatory mediator s, markers of tissue 
damage and m otility-associ ated markers will  be measured presurgery and postsurgery  to evaluate 
TAK -954 treatm ent effects, as needed. Importantly, changes in cortiso l level associ ated wi th 
postoperative nausea
 [13] will be evaluated as well as levels of glucose -dependent insulinotropic 
pepti de (GIP) will also be measured to e xplore its relat ionship wit h vomit ing and/or nausea. 
CONFIDENTIAL
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 33of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALRationale for Blood Sampling for DNA
Blood sam pling for DNA analysis may  be conducted to evaluate the contribut ion of genet ic 
variance on drug response, for example, its efficacy and safet y. Parti cipat ion of  study  subjects in 
blood sam pling for DNA sample co llection is optional.
As geno mics is an evo lving science, current ly many genes and their funct ion are not y et fully 
understood. Future data may suggest a role o f some of these genes in drug response o r diseases, 
which may  lead to addi tional hypothesis -generating exploratory  research on stored samples. 
4.3 Benefit -Risk Profile
Study  parti cipants undergoing open or laparoscopic -assisted partial small -or large-bowel  
resection and receiving TAK -954 m ay exper ience an accelerat ion of the recovery  of GI f unction 
(motilit y) postsurgery . Thi s may resul t in decreased time to tolerance to food ingest ion, decreased 
symptoms of slow GI motilit y (nausea, vo miting, bloating, constipat ion), earlier hospital discharge, 
and decreased readmissio ns for symptom s of decreased GI motilit y.
Overall, TAK -954 i s generally  well tol erated at oral dosing up to 5 mg (for 10 days) and at IV 
dosing up to 2 mg, based upon overall clinical safety  assessment. Aggregate AE review across 
clinical studies conducted to date shows that there were no deaths related to TAK -954 and a very  
low rate of severe AEs or AEs leading to study  drug discont inuat ion. In an aggregate review o f 
SAEs, all but 2 SAEs were considered not related to study  drug by  the invest igator: 1 subject 
reported 2 SAEs (anastomotic leak and GI stoma complicat ion) which were assessed as related to 
the blinded study  treatm ent drug (TAK -954 or pl acebo) by  the invest igator in this study 
(TAK -954- 2004). However, considering the events are commo n complications of extensive bowel 
resection secondary  to underlying malignancy , the 2 seri ous adverse react ions (SARs) were 
assessed as not related to the blinded study drug by the sponsor. Most AEs were mild or moderate 
in severit y, transient, and resolved spontaneously. The most commo n AEs in subjects receiving 
TAK -954 regardless o f doses included headache, nausea, and diarrhea, which were not serious and 
resolved wit hout treatment discont inuat ion, and without indicat ing any clear exposure resp onse. 
Across the studies, a few subjects reported AEs of orthostatic hypotensio n and tachycardia. 
However, these events were nonserious, generally mild or moderate in severit y, usually  of short 
durati on, and resolved spontaneously wit hout significant clini cal concern.
The principal mit igation for these risks includes appropriate select ion of the study  popul ations, 
detailed safet y plan for important potential and ident ified risks, which permits close mo nitoring 
and inst itution of  appropri ate care as needed, and utilizat ion of experienced staff trained in study  
procedures. 
Overall, the benefit -risk profile is therefore considered appropriate for this study .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 34of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL5.0 STUDY OBJECTIVES AND ENDPOINTS
5.1 Objectives
5.1.1 Primary Objective(s)
The primary  object ive of this study  is to assess the efficacy  and safety  of IV TAK -954 f or 
accelerating the recovery  of GI funct ion postsurgery  in pat ients undergo ing open or 
laparoscopic -assisted partial small -or large-bowel  resecti on.
5.1.2 Secondary Objectives
The secondary  objectives of this stud y are:
To determine efficacy and safet y of preoperative dosing of IV TAK -954 rel ative to 
preoperative and postoperative regimens of up to 10 day s of IV TAK -954 f or accelerating the 
recovery  of GI function postsurgery .
To determine the relat ive efficacy and safet y of 0.1 and 0.5 m g IV TAK -954 given either 
preoperatively  alone or preoperatively  and postoperatively  com pared wi th placebo of up to 
10days or resol ution of GI dy sfunct ion postsurgery for accelerat ing the recovery  of GI 
funct ion postsurgery .
To det ermine the PK of TAK -954 in pat ients undergoing major abdo minal surgery.
5.1.3 Exploratory Objectives
The exploratory  objectives are:
To assess the effect of IV TAK -954 on circulating markers of inflammat ion, including but not 
limited to IL -6, IL -10, MCP -1, and CRP postsurgery .
To assess the effect of IV TAK -954 on circulat ing markers associated with GI motilit y and/or 
nausea.
To gain preliminary  estimates of the incidence rate of postoperative complications and 
prolonged POGD ( ≥5 days) based on the type of surge ry (laparoscopic vs open surgery), use of 
opioids, durati on of  surgical  procedure, and ASA scores.
To gain preliminary  estimate of the effect of TAK -954 in prevent ing recurrence of GI 
dysfunct ion postsurgery .
To gain preliminary  estimate of the effect of T AK-954 in prevent ing POGD complicat ions.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 35of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL5.2 Endpoints
5.2.1 Primary Endpoint
The primary efficacy endpo int is time from the end of the surgery to resolut ion of upper and lower 
GI funct ion (ie, time to tol erance of so lid food [defined as first occurrence of no vomit ing or no 
clinically significant nausea for 1 calendar day after a solid meal] and time to first spontaneous 
bowel  movement, whi chever occurs later) up to Day  10 postsurgery .
5.2.2 Secondary Endpoints
The secondary  endpoints for this study  are:
Time fro m the end of the surgery (time the incisio n is closed) unt il ready for discharge (defined 
as the time until the subject presents effect ive intestinal transit [spontaneous bowel mo vement], 
tolerates solids wit hout vomit ing or clinically significant nausea for 1 calendar day after a solid 
meal, has sat isfactory  pain control  with oral analgesics, and is medically  stable/free of 
complicat ions).
Time fro m the end o f surgery  until the discharge order is written.
Time fro m the end o f the surgery  to discharge from hospital.
Time fro m end of surgery  to tol erance of solid food (defined as first occurrence of intake of 
solids without vomit ing or clinically significant nausea for 1 calendar day after a solid meal) up 
to Day  10 postsurgery .
Time fro m end of surgery to first spont aneous bowel mo vement (defined as a stool not induced 
by the use of enemas or laxat ives) up to Day  10 postsurgery .
Percent of subjects with POGD ≥5 days defined as subjects unable to tolerate solid foods, take 
anything by mouth, or requiring insert ion or r einsertion of NG at or after 5 days postsurgery.
Percentage of subjects requiring insertion of NG tube postsurgery , for drainage and symptom 
relief in case of persistent nausea and vo miting postsurgery  up to Day  24 postsurgery  (up to 
10-day treatm ent peri od plus 14 -day observat ion peri od post l ast dose for recurrence of 
symptoms).
Time fro m end of surgery  to fi rst flatus up to Day  10 postsurgery .
Observed plasma concentration of TAK -954 at the end of infusio n on Day  1.
5.2.3 Safety Endpoints
Safety and tol erabilit y will  be evaluated based on the occurrence of AEs, physical examinat ion 
findings, vital signs and weight, ECGs, and clinical laboratory  param eters (chemistry , 
hematol ogy). 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 36of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL5.2.4 Exploratory Endpoints
The exploratory  endpo ints for thi s study will be:
Change in circulating inflammatory  markers including but not limited to IL -6, IL -10, MCP -1, 
and CRP, preoperatively  com pared wi th postoperatively  across different treatm ent groups .
Change in GIP and cortiso l preoperati vely co mpar ed wi th postoperatively across different 
treatm ent groups.
Incidence rate of POGD recurrence for 14 day s post l ast dose.
Percentage of subjects with unplanned hospital readmissio ns due to recurrence of POGD.
Percentage of subjects with postoperative co mplicati ons, such as pneumo nia, acute kidney 
failure, or documented anastomotic leak.
Percentage of subjects requiring reoperation due to postoperative complications.
Health-related qualit y of life as measured by 12 -Item Short Form Health Survey (SF -12) and 
EuroQol  5-Dimensio ns Quest ionnaire (EQ -5D).
Percentage of subjects with postoperative nausea and vo miting (PONV) within 24 hours after 
surgery , from Day  2 until  discharge and at follow -up; defined as pat ients present ing wit h 
emetic events (nausea, vomit ing, or retch ing) or requiring use of ant iemetics.
Peak nausea severit y score from  Day  1 until  discharge using a numerical rat ing scale.
Time fro m the end of the surgery to the first insertion of NG tube (for those requiring insert ion 
of NG tube postsurgery ).
Percentag e of subjects present ing complicat ions or prol onged POGD ( ≥5 days) based on 
opioid use, ty pe of surgery , durati on of  the surgical  procedure, and ASA scores.
6.0 STUDY DESIGN AND DES CRIPTION
6.1 Study Design
This phase 2, randomized, placebo -controlled, parallel 5 -group, doubl e-blind study  is designed to 
determine: (1) if TAK -954 decreases the duration of GI dysfunction in patients undergo ing major 
abdo minal open or laparoscopic -assisted surgeries that invo lve significant bowel manipulat ion, (2) 
whether preoperative dosing alo ne or a preoperative and postoperative dosing regimen is the most 
effect ive dosing regimen to decrease the duration of POGD and improve clinical outcomes, and (3) 
the most appropri ate dose and dosing regimen to advance into phase 3.
Subjects wil l be rando mized in a 1:1:1:1:1 ratio into 1 of 5 parallel treatment groups:
Regimen 1: Placebo (normal saline 100 mL infusio n over 60 minutes) preoperation and daily  
postoperation until return of upper and lower GI funct ion (ie, resolut ion of POGD) or for up to 
10 day s.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 37of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALRegimen 2: TAK -954 (0.1 m g/100 mL infusio n over 60 minutes) preoperation and daily 
postoperation until return of upper and lower GI funct ion or for up to 10 day s.
Regimen 3: TAK -954 (0.5 m g/100 mL infusio n over 60 minutes) preoperation and d aily 
postoperation until return of upper and lower GI funct ion or for up to 10 day s.
Regimen 4: TAK -954 (0.1 m g/100 mL infusio n over 60 minutes) preoperation and daily 
placebo infusio ns postoperation unt il return of upper and lower GI funct ion or for up to
10days.
Regimen 5: TAK -954 (0.5 m g/100 mL infusio n over 60 minutes) preoperation and daily 
placebo infusio ns postoperation unt il return of upper and lower GI funct ion or for up to 
10days.
Subject randomizat ion will be stratified by  laparoscopi c and open surgery  procedures.
With this Protocol Amendment 5, the planned total sample size is approximately 180 subjects. 
Two of the above TAK -954 regimens are di scont inued based on IMC recommendations. As a 
resul t, eligible subjects will be equally rando mized to into 1 of 3 of the remaining parallel 
treatm ent groups:
Regimen 1: Placebo (normal saline 100 mL infusio n over 60 minutes) preoperation and daily  
postoperation until return of upper and lower GI funct ion (ie, resolut ion of POGD) or for up to 
10 day s
Regime n 3: TAK -954 (0.5 m g/100 mL infusio n over 60 minutes) preoperation and daily 
postoperation until return of upper and lower GI funct ion or for up to 10 day s.
Regimen 5: TAK -954 (0.5 m g/100 mL infusio n over 60 minutes) preoperation and daily 
placebo infusio ns postoperati on unt il return of upper and lower GI funct ion or for up to 
10days.
It is standard of practice for the postoperative care of patients after colorectal surgery to implement 
an ERP to reduce the time to recovery  of GI f unction (motilit y). To pr ovide a consistent ERP as 
baseline therapy  for all  subjects, they  will receive the same core features of an ERP for 
postoperative care as outlined below:
Core ERP:
Minimize opio id use while maintaining adequate pain control through use of mult imodal 
analge sia. Suggested analgesics include opio id alternat ives, such as nonsteroidal 
anti-inflammatory  drugs (eg, ketorolac tromethamine IV), acetaminophen (paracetamol), or 
oral pregabalin, when possible. It is recommended that at least 2 different analgesics with
different mechanism of act ion are tri ed and failed before prescribing opio ids.
Maintenance of euvo lemia and normal salt and electroly te state in peri operative peri od.
No routine use of prophylact ic NG tubes postsurgery. NG tubes should only be used if there is 
a docum ented medical reason to just ify them.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 38of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALUse of a standardized risk- based strategy  for PONV prophylaxis: use of preoperative 
antiemetic prophylaxis in pat ients with 1 or m ore risk factors of the simplified Apfel Score 
(female gender, planned p ostoperative use of opioids, nonsmokers, history  of PONV/m otion 
sickness).
Early oral feeding postsurgery  when possible. Clear liquids after the surgery  on Day  1, 
advancing to soft diet on Day  2 if tol erant to li quids (no nausea or vomit ing).
Early mo bilization starting after the surgery  on Day  1 when possible.
Schemat ics of the study design prior to Protocol Amendment 5 can be found in Figure 6.aand wit h 
the discont inuation of  2 treatm ent regimens and remo val o f the second IA in
 Figure 6.b. A 
schedule of assessments is listed in Appendix A.
Figure 6.a Schematic of Study Design Prior to Protocol Amendment 5
Abbreviations: IA, interim analysis; PBO, placebo.PBO
T1*
T2*
T3*25
25
25
25IA #1 
Decisions based 
on efficacy and 
safety of each arm 
(potential study 
modification 
including futility, 
dose adjustment, 
dose/dosing 
regimen decisions, 
and sample size 
adjustments).
Validation of 
power calcula ion
Doses/regimens may be modified.PBO
TO1**
TO2**+ 25, T otal: 50
+ 25, T otal: 50
+ 25, T otal: 5025 subjects/ arm
Total: 125 subjectsAdd 25 subjects/ arm
Total: up to 225 subjects
IA #2
Decisions based 
on efficacy and 
safety of each arm 
(Goal is to identify 
the most 
promising/safe 
dose/regimen ).
Valida ion IA #1PBO+50, T otal: 100Add 50 subjects/ arm
Total: up to 375 subjects
TOX***+50, T otal: 100
TOY****+50, T otal: 100
(Possible )
T1 = TAK -954 0.1 mg/100 mL infusion preoperative and daily
T2 = TAK -954 0.5 mg/100 mL infusion preoperative and daily
T3 = TAK -954 0.1 mg/100 mL infusion preoperative only 
T4 = TAK -954 0.5 mg/100 mL infusion preoperative only Doses/regimens may be modified.
**TO1 & TO2 & TO3 = Optimal 
dose carried over after IA #1***TOX = Optimal dose continues after IA #2.
****TOY = Could continue if deemed 
valuable as alternative dose.T4*25TO3**+ 25, T otal: 50
(Possible)
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 39of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALFigure 6.b Schematic of Study Design By Protocol Amendment 5
Abbreviations: IA, interim analysis; PBO, placebo.
Criteria for resolut ion of upper and lower GI funct ion is time to first tolerance of so lid food 
(defined as no vo miting or no clinically significant nausea for 1 calendar day  after a solid m eal) 
and time to first spontaneous bowel movement, whichever occurs later, up to Day 10 postsurgery. 
Following hospi tal discharge, subjects will be instructed to contact their physici an if they have 
recurring symptoms suggest ive of POGD to evaluate the need for hospital readmissio n in case of 
relapse. All subjects will return to the clinic 14 days (±4 days) post last dose; however, during the 
COVID -19 public healt h emergency , the f ollow-up visi t 14 day s post l ast dose m ay be conducted 
via phone call (eg, collect ion of AEs, concomitant medicat ions, and monitoring) to extend 
flexibilit y to study  subjects. In the case of a phone call fo llow-up, physical examinat ion (including 
neuro logy examinat ion), vital signs, or pregnancy test would not be collected; however, AEs will 
be assessed, including a safet y check on any emerging clinical signs or symptoms. Subjects may be 
requested to return to the site for further safet y assessment, due to repo rted AEs, at the 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 40of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALinvestigator’s discret ion. The ty pe of visit (whether clinic visit or phone call) must be recorded in 
the study records. Qualit y of life assessments will be completed by the subject in their ho me o n the 
same day  as the safet y follow-up cal l and co mpleted questionnaires will be mailed to the clinic. 
Subjects will be contacted by phone 30 (±3 days) and 90 (±7 days) days posttreatment for a safet y 
follow-up.
Two prepl anned IAs will be conducted when a priori enrollment goals have been achieved . 
Bayesian approach will be applied after these IAs for decisio n making for potential study  
modificati on including fut ility, dose and dosing regimen decisio n, and sample size adjustment. In 
case dose m odificat ion is needed after the IA, the maximal dose fo r potential modificat ion of 
doses/regimens will be 1.0 mg. The duration o f drug administration (up to 10 days postsurgery) 
will not be changed. By this protocol  amendment, the second IA is remo ved fro m the protocol.
6.2 Justification for Study Design, Dose, an d Endpoints
Rationale for Study Design
The proposed adaptive design wit h bayesian approach has several benefits over tradit ional design 
and frequent ist method. Adaptive designs have become popular in clinical trials because o f its 
advantages of flexibilit yand efficiency  gains, some of which also have the significant advantage 
of enro lling fewer patients to treatment arms wit h inferior outcomes.
Rationale for Dose
TAK -954 IV doses of 0.1 and 0.5 mg QD preoperatively and postoperatively for up to 10 days and
0.1 and 0.5 mg single doses preoperative administration were selected to be studied in this dose 
and dosing regimen study . These doses are expected to allow the characterizat ion of the 
exposure/response (efficacy and safet y) relationship for TAK -954. The exposure/response data 
generated fro m these dosing regimens will provide informat ion for selecting optimal doses for 
future studies and dosing regimen and to maximize benefit/risk ratio. Several factors have been 
taken into accoun t when selecting the doses and dosing regimen ment ioned above, including 
safet y, tolerabili ty, PK, and pharmacodynamic (PD) data from healt hy vo lunteers and crit ically -ill 
patients wi th delayed gastric empt ying. TAK -954 was generally well tolerated in healt hy 
volunteers following 0 .5 mg IV administered for 5 days. TAK -954 0.1 and 0.5 mg doses appeared 
to reduce the time to first bowel movement and increase the number of bowel mo vements on the 
first day  of dosing in healt hy subjects. When co mpared wi th metocl opramide 10 m g IV every  6
hours, a single dose of 0.5 mg IV TAK -954 also dem onstrated a consi stent pattern to enhance 
gastri c empt ying in crit ically ill pat ients with delayed gastri c emptying.
All available efficacy, safet y, and tol erabili ty data will  be consi dered to determine po tential 
changes to dose or regimen after each IA. The potent ial durat ion of drug administration (up to 
10days postsurgery ) will  not be changed. Addit ionally , the basic regimen (preoperation 
administration and postoperation administration) will not be alte red.
Preliminary data suggest that a prokinetic and ant i-inflammatory  effect i s achieved wit h 0.5 mg. 
Addit ionally , resul ts fro m a completed scint igraphy study assessing the effect TAK -954 on gastric 
emptying, small bowel and colonic transit, as well as th e safet y and tolerabilit y of doses of 0.1, 0.3, 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 41of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALand 1.0 m g QD IV in patients with gastroparesis (TAK -954- 2003), will be considered during the 
IA. This informat ion, along with the IA results, will be used to decide if adjust ments to the current 
doses tested in the TAK -
954-2004 study  are warranted. 
The maximum dose that could potentially be used in the TAK -
954-2004 study  is 1.0 mg QD by IV 
administration. Based on the principle of superposition, the predicted maximum concentration 
during a dosing interval, a t steady  state (C max,ss) and area under the concentration -time curve from 
time 0 to 24 hours, at steady  state (AUC 24,ss) for TAK -954 1.0 m g QD IV dosing provides an 
approximately  41-fold/851 -fold margin relat ive to total/free C maxat the no-observed -effect level in 
the dog cardiovascular (CV) study , 468 -fold margin relat ive to AUC 24in the rat 13 -week 
repeat -dose study at the no -observed -adverse -effect level (NOAEL), and 250
-fold margin relat ive 
to AUC 24in the rabbit embryo -fetal-devel opment study  at the N OAEL, respectively. These 
exposures are approximately  one-third to one -half of the exposures that were achieved with 5 mg 
QD oral dosing for 10 days in healt hy subjects (maximum tolerated dose).
Rationale for Endpoints
All patients undergoing an abdo minal surgical procedure will inevitably develop a transient 
episode of impaired GI motilit y (tradi tionally  referred to as POI) and stasis of the intraluminal 
contents [14]. In some cases, this may result in nausea, vo miting, bloat ing, delay ed passage of 
stool  and inabilit y to tol erate liquid or solid foods. Normally, inhibit ion of small bowel motilit y is 
transi ent and the stom ach recovers within 24 to 48 hours, whereas colonic function takes 48 to 72 
hours to return [14]. The duration of this impaired mot ility reflects the clinical recovery  of the 
patient. Determinat ion of the end of POGD (or POI) has been so mewhat con troversi al as different 
studi es have tri ed to i dentify the return of normal bowel motilit y with unreliable and poorly  
specific clinical endpo ints such as time to first flatus or return of bowel sounds. Using scint igraphy, 
van Bree et al [
15]have shown that the return of gastric empt ying is reflective of the abilit y to 
tolerate solid food, and t hat the occurrence of the first solid stool reflects return of lower GI 
motility. The co mbined outcome measure of tolerance o f solid food and having had defecat ion 
(area under the concentration -time curve = 0.9, SE = 0.04, 95% CI = 0.79 -0.95, p <0.001) bes t 
indicated recovery  of GI transi t with a posi tive predi ctive value of 93% (95% CI =
78-99). They 
further validated this endpo int using data from a mult icenter trial o f 320segmental  colectomy 
patients in which mult iple regressio n analysis revealed that ti me to first stool and so lid food 
tolerance best predicted the duration of hospital stay. Therefore, the primary endpo int in this study 
will assess the duration of t ime to tolerance of so lid food and time to the first spontaneous bowel 
movement (whichever o ccurs later) which reflects a clinically meaningful return of GI 
funct ion/motility.
6.3 End of the Study
The overall study  ends when the l ast subject com pletes the l ast pl anned or follow -up 
visit/interact ion associated with a planned visit (this can be a phone contact), discont inues fro m the 
study , or is l ost to foll ow-up (ie, the invest igator is unable to contact the subject).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 42of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL6.4 Premature Termination or Suspension of Study or Study Site
6.4.1 Criteria for Premature Termination or Suspension of the Study
The study  will be co mpleted as planned unless 1 or more of the fo llowing criteria are satisfied that 
requi re tem porary  suspensi on or early  terminat ion of the study .
New informat ion or other evaluat ion regarding the safet y or efficacy  of the study  drug that 
indicates a change in the known risk/benefit profile for the TAK -954, such that the risk is no 
longer acceptable for subjects participat ing in the study .
Futility demo nstrated at IA.
Significant vio lation of Good Clinical Practice (GCP) that compromises the abilit y to achieve 
the primary  study  objectives or compromises subject safet y.
6.4.2 Criteria for Premature Termination or Suspension of Study Sites
A study  site may  be terminated prematurely  or suspended if the site (including the invest igator) is 
found in significant vio lation of GCP, protocol, or contractual agreement, is unable to ensure 
adequate enrollment or performance of the study , or as otherwi se permi tted by  the contractual  
agreem ent.
6.4.3 Procedures for Premature Termination or Suspension of the Study or the 
Participation of Study Site(s)
In the event that the sponsor, an inst itutional review board (IRB)/independent ethics committee 
(IEC) or regulatory authorit y elects to terminate or suspend the study or the participat ion of a study 
site, a study -specific procedure fo r early terminat ion or suspensio n will be provided by the sponsor; 
the procedure will be fo llowed by applicable study sites during the course of terminat ion or study  
suspension.
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS
7.1 Inclusion Criteria
1.In the opinion o f the invest igator, the subject is capable of understanding and complying wit h 
protocol  requi rements.
2.The subject signs and dates a written, informed consent form and any  requi red privacy 
authori zation prior to the init iation o f any study  procedu res. 
3.The subject is scheduled to undergo a laparoscopic -assisted, or open partial small -or 
large -bowel , resecti on.
4.The subject is male or female and is at least 18 y ears ol d.
5.The subject’s ASA physical status classificat ion is ASA 1 to 3.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 43of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL6.A female subjec t of childbearing potential* who is sexually act ive with a nonsterilized* male 
partner agrees to use a highly effective method of contraception* fro m signing o f informed 
consent throughout the duration of the study  and for up to 30 day s posttreatm ent.
*Def initions and highly  effect ive methods of contraception are defined in 
Secti on9.1.13 and reporting responsibilit ies are defined in Sect ion 9.1.14 .
7.2 Exclusion Criteria
Any subject who meets any  of the fo llowing cri teria will not qualify  for entry  into the study : 
1.The subject has received any invest igational co mpound within 30 days pri or to screening.
2. The subject has received TAK- 954 in a previous clinical study  or as a therapeutic agent.
3.The subject is an immediate family member, study site emplo yee, or i s in a dependent 
relationship with a study  site em ployee who i s involved i n conduct of this study  (eg, spouse, 
parent, child, sibling) or may consent under duress.
4. The subject has significant mechanical bowel obstruction that is not expected to resolve after 
the surgery , short bowel syndro me, pre -exist ing clinically significant GI motilit y disorder (eg, 
gastroparesi s, scleroderma, chronic intest inal pseudo -obstructi on), uncontrolled diabetes 
(glycosylated hemoglo bin [HbA1c] >10%), has an active gastric pacemaker, or requires 
parenteral  nutri tion.
5. The subject had previous major ab dominal  surgery (eg, gastrectomy , gastri c bypass, gastri c 
sleeve, l ap banding, Whipple, pancreat ic resect ion, total/subtotal colectomy, hemico lectomy , 
extensive bowel resection). 
6.The subject has a history  of radiati on therapy  to the abdom en or pelvis.
7.Thesubject is scheduled to undergo any of the fo llowing surgeries: low anterior resection, total 
or subtotal co lectomy, colostomy, ileostomy, or reversal o f stom a or has a di agnosis that 
requi res rectal  resecti on (eg, tum ors in the anorectum) and will likely require l ower anteri or 
resection surgery . Subjects wi th planned surgery  for whi ch there is no ant icipated significant 
rectal  resect ion and i s, therefore, likely  to preserve anorectal  function and cont inence 
postsurgery , will likely be eligible for inclusi on in the study  if they meet all  the study  
inclusio n/excl usion criteria (eg, subjects with lesio ns not invo lving the rectum [sigmo id colo n 
and above]). 
8.The subject has pre -exist ing hepat ic disease that meets Child -Pugh Class B (moderate; total 
score 7 to 9 points) or C (severe; total score 10 to 15 points).
9.The subject has alanine aminotransferase (ALT) and/or aspartate aminotransferase 
(AST) >3 ×upper limit of normal (ULN), or total bilirubin >2 ×ULN.
10.The subject has an est imated glo merular filtrat ion rate <30 mL/min.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 44of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL11.The subject has received alvimopan, ery thromycin,  prucalopride, metoclopramide, 
domperidone, ci sapride, m osapri de, renzapri de, or azi thromycin in the 24 hours prior to 
starting study  drug.
12.The subject has a resting heart rate of <50 beats p er minute (bpm).
13.The subject has clinically significant ECG abnormalit ies indicat ive of cardiac conduct ion 
abnorm ality or acute cardi ac instabilit y as determined by  the invest igator at screening; more 
than first degree atrioventricular (AV) block; >5 beats of nonsustained ventricular tachycardia 
(VT) at a rate >120 bpm; or ECG changes consistent with acute myocardial ischemia or 
infarction.
14.The subject has a QT interval with Fridericia correction method (QTcF) ≥450 msec or other 
factors that increase the ri sk of QT prolongat ion or arrhythmic events at screening. The records 
of subjects with bundle branch block and a prolonged QTcF should be reviewed by a medically 
qualified person in consultat ion with the m edical m onitor and the sponsor for potential 
inclusi on.
15.The subject has known COVID -19 infect ion, or suspected COVID -19 infection (as assessed by 
the invest igator).
16.The subject has any  other si gnificant uncontrolled organic or sy stemic medical condit ion or 
social circumstance that, in the invest igator’s opi nion, would mean it was not appropriate for 
the subject to participate in this clinical study .
17.The subject is scheduled for abdominal surgery that is classified as emergency.
18.The subject had acute my ocardial  infarct ion or ischemia wit hin the past 12 months. Subjects 
with increased cardiac risks for surgery  including coronary  artery  disease or pri or my ocardial  
infarction and evidence of reduced left ventricular funct ion or history  of angina shoul d be 
assessed by  the invest igator for stabilit y and contr ol of their cardiac condi tion and ri sk of  
surgery , and excluded if in the invest igator’s opinion, participat ion in the study is not 
considered appropriate. The sponsor should be consulted if subjects with these condit ions are 
considered by the investigator to be acceptable.
19.The subject had pulmo nary embo lism, deep venous thrombosis, or mechanical ventilat ion for 
any medical condit ion within the past 12 months. Subjects with a history  of multiple venous 
thrombosis or pulmo nary embo lic events, history  of a hy percoagul able condi tion, history  of 
severe exacerbat ion for chroni c obstructive pulmo nary disease or evi dence of pulmo nary 
hypertensio n should be assessed by the investigator for stabilit y and control of their condit ions 
and risk of surgery , and excluded i f in the invest igator’s opinio n, parti cipat ion in the study  is 
not consi dered appropri ate. The sponsor should be consulted if subjects with these condit ions 
are considered by  the invest igator to be acceptable.
7.3 Excluded Medications
The fo llowing m edicat ionsare excluded from 24 hours prior to starting study  drug to 5 days post 
last dose of study  drug .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 45of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALLaxatives (preoperative bowel preparations are not excluded).
Prokinetic agents: domperidone, erythro mycin, azithromycin, and 5 -HT 4agonists (cisapride, 
mosapri de, prucal opride, renzapride, and metoclopramide).
µ-Opioid antagonist : Alvimopan.
7.4 Criteria for Discontinuation or Withdrawal of a Subject
The primary  reason for di scont inuat ion or wi thdrawal  of the subject from  the study  or study drug 
shoul d be recorded in the electronic case report form (eCRF) using the following categories. For 
screen failure subjects, refer to Section 9.1.19 .
1.Treatment discont inuat ions due to an AE: The subject has experienced an AE that requires 
early  terminat ion because continued participat ion imposes an unacceptable risk to the subject’s 
healt h or the subject is unwilling to continue because of the AE. Specific event s that require 
treatm ent discont inuat ion (see Section 10.1.6 )  include:
Prolonged QT: Second episode of Grade 2 (QTcF >480 and ≤500 msec), any occurrence o f 
Grade 3 (QTcF >500 msec, or >60 msec change from baseline) or Grade 4 (Torsades de 
pointes or polymorphic ventricular tachy cardi a or si gns/symptom s of seri ous arrhy thmia).
Second or third -degree heart block: Treatments with study  drug may  be cont inued in 
second -degree heart block Mobitz I (Wenckebach) after medical mo nitor revi ew.
Any occurrence of Grade 4 (life -threatening) supraventricular tachy cardi a (SVT) that i s 
considered related by  the invest igator.
Suspected serotonin syndro me.
Liver test abnormalit ies: Tre atment wi th study  drug shoul d be di scontinued in subjects 
who develop ALT or AST >3 ×ULN concurrently with total bilirubin >2 ×ULN while on 
treatm ent wi th study  drug. These findings should be reported to the sponsor as a serious 
adverse events of special interest (AESI). The investigator must contact the medical 
monitor for discussio n of the relevant subject details and possible alternat ive etio logies, 
such as acute viral hepatit is, other acute liver disease, or medical history/concurrent 
medical condit ions. In addit ion, the invest igator should contact the medical monitor for 
any increase in liver tests without clear etio logy.
Known COVID- 19 infect ion.
2.Significant protocol deviat ion. The discovery postrando mizat ion that the subject failed to meet  
protocol  entry  criteria or di d not adhere to protocol requirements, and continued participation 
poses an unacceptable risk to the subject’s health.
3. Subject did not receive 2 or more doses of the assigned randomized treatment.
4.If the subject, due to intraoperative c ircumstances, has surgery  that resul ts in a si gnificant 
resection o f rectal  tissue, a >50% resection of colon tissue, or an ostomy , study  drug dosing 
shoul d be discont inued.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 46of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL5.Voluntary  withdrawal. The subject wishes to withdraw from the study  or study drug. The 
reason for withdrawal, if provided, should be recorded in the eCRF.
Note: All attempts should be made to determine the underlying reason for the withdrawal and, 
where possible, the primary  underlying reason should be recorded (ie, withdrawal due to an
AE should not be recorded in the “vo luntary withdrawal” category ). Similarly, lack o f efficacy 
shoul d not be recorded in the “vo luntary withdrawal ” category . Addi tional efforts shoul d be 
made and documented to encourage subject to participate in the fo llow-up portion of the study.
6.Study  terminat ion. The sponsor, IRB, IEC, or regulatory  agency  terminates the study .
7.Pregnancy. The subject is found to be pregnant .
Note: If the subject is found to be pregnant, the subject must be withdrawn immediately. The 
procedure is described in Sect ion 9.1.14 .
8.Lack of efficacy. The invest igator has determined that the subject is not benefit ing from study 
treatm ent; and, continued pa rticipat ion would pose an unacceptable risk to the subject. 
9.Other.
Note: The specific reasons should be recorded in the “specify” field of the eCRF.
7.5 Procedures for Discontinuation or Withdrawal of a Subject
The invest igator may discont inue a subject’s study drug participation at any time during the study 
when the subject meets the study  drug terminat ion criteria described in Section 7.4.  In addi tion, a 
subject may discont inue his or her participat ion without giving a reason at any  time during the 
study . Shoul d a subject’s participat ion be discont inued, the primary criterion for study drug 
termination must be recorded by the invest igator. 
In addit ion, efforts should be made to perform all procedures scheduled for the early termination 
visit. Every  effort shoul d be m ade to perform  the foll ow-up visit s at 14, 30, and 90 day s post l ast 
dose for every  dosed subject, as noted in the Schedule of Study Procedures ( Appendix A). For 
subjects who did not receive study  drug, the fo llow-up vi sits do not need to be completed. 
8.0 CLINICAL STUDY MATER IAL MANAGEMENT
8.1 Study Drug and Materials
8.1.1 Dosage Form, Manufacturing, Packag ing, and Labeling
In thi s protocol , the term  study  drug refers to all or any  of the drugs defined below.
8.1.1.1 TAK-954
The drug product, TAK -954 Inject ion (Concentrate for Solut ion for Infusio n), consists of a clear 
colorless solut ion of TAK -954 free base in cle ar Type I glass vials fitted with a rubber stopper and 
sealed wit h an a luminum cap. The drug product is formulated as 0.1 mg/mL o f TAK-954 free base 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 47of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALequivalent dissolved in water for inject ion, adj usted to pH 5.0 with hydrochloric acid and/or 
sodium hydrox ide. Each glass vial contains 5.5 mL of sterile TAK -954 sol ution designed to 
deliver no minally 5.0 mL o f the so lution. The drug product solut ion is intended to be diluted to the 
requi red concentration with normal saline (0.9% sodium chloride for inject ion), for IV infusio n. 
Norm al saline is used as placebo.
TAK -954 cartons and vials will be affixed with labels that are in accordance wit h regulatory 
requi rements.
8.1.1.2 Ancillary Materials
All ancillary supplies will be provided by either the site or the sponsor, b ased upon availabilit y. If 
provi ded by the sponsor, unused ancillary  supplies will be accounted for and disposed of as 
directed by  the sponsor or a designee.
8.1.2 Storage
Study  drug m ust be kept in an appropriate, limited -access, secure place unt il it is used o r 
authori zed for destruction by  the sponsor or desi gnee. Study  drug m ust be stored under the 
condi tions specified on the label, and remain in the original container unt il dispensed. A daily 
temperature l og of  the drug storage area must be maintained every working day . The requi red 
storage condit ion for TAK -954 study  drug i s refrigerati on between 2°C and 8°C. 
8.1.3 Dose and Regimen
Subjects will be rando mized 1:1:1:1:1 into 1 of 5 treatment groups. Adjust ments to the treatment 
groups m ay be made based on IA resul ts.
Following the discontinuation o f 2 treatment groups (see Section 6.1) , subjects will be rando mized 
to 1:1:1 into 1 of 3 remaining treatment groups by  Protocol  Amendment 5 (see Section 6.1).
Addit ional information regarding the dosing instructions for TAK -954 can be found in the 
pharmacy manual.
Table 8.adescribes the dosing regimens in the protocol and  Table 8.bdescribes the dosing 
regimens remaining after discontinuing 2 dosing groups as clarified in this protocol amendment.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 48of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALTable 8.a Dose and Regimen Prior to Protocol Amendment 5
Treatment 
Group Dose Treatment Description
1 Placebo (100 mL saline infusion over 
60 minutes)Given preoperation and daily postoperation for up to 10 days 
or until return of upper and lower GI function.
2 TAK -954 (0.1 mg/100 mL infusion 
over 60 minutes)Given preoperation and daily postoperation for up to 10 days 
or until return of upper and lower GI function.
3 TAK -954 (0.5 mg/100 mL infusion 
over 60 minutes)Given preoperation and daily postoperation for up to 10 days 
or until return of upper and lower GI function. 
4 TAK -954 (0.1 mg/100 mL infusion 
over 60 minutes)Given preoperation and daily placebo infusions postoperation 
for up to 10 days or until return of upper and lower GI 
function.
5 TAK -954 (0.5 mg/100 mL infusion 
over 60 minutes)Given preoperation and daily placebo infusions postoperation 
for up to 10 days or until return of upper and lower GI 
function.
Abbreviations: GI, gastrointestinal.
Table 8.b Dose and Regimen as a Result of Protocol Amendment 5
Treatment 
Group Dose Treatment Description
1 Placebo (100 mL saline infusion over 
60 minutes)Given preoperation and daily postoperation for up to 10 days 
or until return of upper and lower GI function.
3 TAK -954 (0.5 mg/100 mL infusion 
over 60 minutes)Given preoperation and daily postoperation for up to 10 days 
or until return of upper and lower GI function. 
5 TAK -954 (0.5 mg/100 mL infusion 
over 60 minutes)Given preoperation and daily placebo infusions postoperation 
for up to 10 days or until return of upper and lower GI 
function.
Abbreviations: GI, gastrointestinal.
On Day  1, the com pletion of the infusio n shoul d occur wi thin 3 hours of the start of surgery  
(induction o f anesthesia). Subsequent doses (Days 2 to 10, if required) should be approximately 24 
hours (±5 hours) fro m the start of the prior infusion. If a subs equent dose cannot be administered 
during thi s window, it shoul d be skipped. 
8.1.4 Overdose
An overdose is defined as a known deliberate or accidental administration of study drug, to or by a 
study  subject, at a dose above that which is assigned to that individ ual subject according to the 
study  protocol .
All cases of overdose (with or without associated AEs) will be documented on an Overdose page 
of the eCRF, in order to capture this important safety  information consistent ly in the database. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 49of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALCases of overdose wi thout m anifested si gns or symptoms are not considered AEs. AEs associated 
with an overdose will be documented on AE CRF(s) according to Section 10.0.
SAEs associated with overdose should be reported according to the procedure outlined in 
Secti on10.2.2 .
TAK -954 has been invest igated in clinical studies up to 20 mg or ally. AEs observed at 5 mg orally 
(with a mean exposure approximately 4 -fold higher than that for IV dosing at 0.5 mg) or higher 
included mild orthostatic hypotensio n in 1 subject after they received a single oral 5 mg dose and 
mild AV dissociat ion in 2 su bjects after they  received a single oral 10 mg dose. In the event of an 
IV overdose, discont inue the treatment of study drug, treat the subject symptomat ically and 
provi de supportive care as needed.
8.2 Study Drug Assignment and Dispensing Procedures
In order to maintain the blind, all study  site personnel except the investigational pharmacist or 
designee will be blinded to subject treatment assignments for the duration of the study. A member 
of the invest igator staff will ut ilize the IRT to randomize the subje ct into the study . During this 
contact, the staff member will provide the necessary subject -ident ifying informat ion, including the 
subject number assigned at screening. Subjects will be assigned in a 1:1:1:1:1 ratio to receive the 
treatm ents or pl acebo, TA K
-954 0.1 or 0.5 mg preoperation, or TAK -954 0.1 or 0.5 mg 
preoperati on and postoperation daily for up to 10 days or until the return of upper and lower GI 
funct ion. By  Protocol  Amendment 5, subjects will be assigned in a 1:1:1 ratio to receive the 
treatm ents or pl acebo, TAK -954 0.5 m g preoperation, or TAK -954 0.5 m g preoperati on and 
postoperation daily for up to 10 days or until the return of upper and lower GI funct ion. The study 
drug assignment will be emailed to the unblinded pharmacist only . Unblinded invest igator staff 
shoul d not be invo lved with any study procedures or assessments other than those related to study 
drug m anagement (eg, di spensing, preparation, accountabilit y, etc.). Similarly, blinded 
investigat ional staff should not have access to pha rmacy documentation or interact with pharmacy 
staff in a manner which could unblind them to subject treatment assignment. 
Subject randomizat ion will be stratified by  laparoscopi c and open surgery  procedures.
Subjects will be assigned to receive their trea tment according to the randomizat ion schedule 
allocated to each study  site. 
Specific procedures related to treatment assignment/dispensat ion, requests for resupply o f study  
drug, or reporting of lost or damaged shipments of study  drug are outlined in the study  manual . 
8.3 Randomization Code Creation and Storage 
Randomization personnel of the sponsor/ the designee o f the sponsor will generate the 
rando mizat ion schedule and will provide it to the IRT vendor before the start of this study . All 
rando mizat ion information will  be stored in a secured area, accessible only  by authori zed 
personnel.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 50of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL8.4 Study Drug Blind Maintenance
The study  drug blind will be maintained using the IRT.
Since the maintenance of the blind may be co mpromised because of results fro m drug 
conce ntrations and/or PD assessments, such results should not be disclosed before formal 
unblinding of study . In the event that results must be reported to the invest igator before breaking 
the blind, all efforts should be made to maintain the blind (eg, as chan ging a medicati on 
ident ificat ion [ID] number in order to avoid ident ificat ion of subjects by the laboratory  site 
personnel).
8.5 Unblinding Procedure
The study  drug blind shall not be broken by  the investi gator unl ess inform ation concerning the 
study  drug i s necessary for the medical treatment of the subject. All study  assessments and 
causalit y assessments should be perform ed, if possible, before unblinding. In the event of a 
medical emergency, if possible, the medical mo nitor should be contacted before the stu dy drug 
blind is broken to discuss the need for unblinding.
For unblinding a subject, the study drug blind can be obtained by the invest igator, by accessing the 
IRT. 
The sponsor must be notified as soon as possible if the study drug blind is broken. The date, time, 
and reason the blind is broken must be recorded in the source documents and the same informat ion 
(except the time) must be recorded on the eCRF.
If any site personnel are unblinded, study drug must be stopped immediately and the subject must 
bewithdrawn fro m the study . 
Placebo PK samples will not be analyzed; therefore, the randomizat ion code will be sent to the 
analyzing laboratory .
8.6 Accountability and Destruction of Sponsor- Supplied Drugs
Drug supplies will be counted and reconciled at the si te before being returned to the sponsor or 
designee or destroy ed locally.
The investigator or designee must ensure that the sponsor -supplied drug is used in accordance wit h 
the protocol and is dispensed only to subjects enro lled in the study . To docum ent a ppropri ate use 
of sponsor -supplied drug, the invest igator or designee must maintain records of all 
sponsor -supplied drug delivery to the site, site inventory, dispensat ion and use by each subject, and 
return to the sponsor or designee.
Upon receipt of spon sor-supplied drug, the invest igator or designee must verify the contents of the 
shipments against the packing list. The verifier should ensure that the quantit y is correct, and the 
medicat ion is in good condit ion. If quant ity and condit ions are acceptable, invest igator or designee 
shoul d acknowl edge the recei pt of the shipment as instructed per the documentation 
accompanying the shipment. If there are any  discrepancies between the packing list versus the 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 51of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALactual product received, the sponsor or its designee must be contacted to resolve the issue. The 
packing list should be filed in the invest igator’s essential document file.
The invest igator or designee must maintain 100% accountabilit y for all sponsor -supplied drugs 
received and dispensed during his or her e ntire parti cipat ion in the study . Proper drug 
accountabilit y includes, but is not limit ed to:
Frequent ly verifying that actual inventory  matches docum ented inventory .
Verifying that the log is completed for the drug lot/medicat ion ID used to prepare each d ose.
Verifying that all containers used are documented accurately on the log.
Verifying that required fields are co mpleted accurately and legibly.
If any dispensing errors or discrepancies are discovered, the sponsor must be notified immediately.
The IRT w ill include all required informat ion as a separate entry  for each subject to whom 
sponsor -supplied drug is dispensed.
The invest igator or designee must record the current inventory of all sponsor -supplied drugs on a 
sponsor -approved drug accountabilit y log. The fo llowing informat ion will be recorded at a 
minimum: protocol number and tit le, name of investigator, site ident ifier and number, descript ion 
of sponsor -supplied drugs, expiry date and amount dispensed including init ials, and signature of 
the person dispensing the drug. The log should include all required informat ion as a separate entry 
for each subject to whom sponsor -supplied drug is dispensed. 
Before site closure or at appropriate intervals, a representative fro m the sponsor or its designee will 
perform  sponsor -supplied drug accountabilit y and reconciliat ion before sponsor -supplied drugs 
are returned to the sponsor or its designee for destruction or destroyed locally. The investigator or 
designee will retain a copy  of the docum entati on regarding sp onsor -supplied drug accountabilit y, 
return, and/or destruction, and originals will be sent to the sponsor or designee.
The invest igator will be notified of any expiry date or retest date extensio n of sponsor -supplied 
drug during the study  conduct. On expir y date notificat ion from the sponsor or designee, the site 
must com plete all  instructi ons outlined in the notification, including segregat ion of expired 
sponsor -supplied drug for return to the sponsor or its designee for destruction or destroyed locally.
In the event of expiry date extensio n of sponsor -supplied drug already at the study site, 
sponsor -supplied drugs may be relabeled with the new expiry date at that site. In such cases, the 
sponsor or its designee will prepare addit ional labels, certificates of analyses, and all necessary 
docum entati on for com pletion of  the procedure at the sites.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 52of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL9.0 STUDY PLAN
9.1 Study Procedures
The fo llowing sect ions describe the study procedures and data to be collected. For each procedure, 
subjects are to be assessed by the sam e investigator or site personnel whenever possible. The 
Schedule of Study  Procedures i s located in Appendix A.  
9.1.1 Informed Consent Procedure
The requi rements of the infor med consent are described in Sect ion 15.2.
Inform ed consent m ust be obtained prior to the subject entering into the study , and before any 
protocol -directed procedures are performed. Informed consent may be performed in clinic or 
remotely  using el ectroni c signature where allowed by  site IRBs/IECs.
A unique subject ident ificat ion number (subject number) will be assigned to each subject at the 
time that informed consent i s obtained; thi s subject number will be used throughout the study .
9.1.2 Demographics, Medical History, and Medication History Procedure
Dem ographic informat ion to be obtained will include date of birth or age, sex, ethnicit y (as 
described by the subject or subj ect’s representative), height, weight, and smoking status of the 
subject at screening. 
Medical history  to be obtained will include determining whether the subject has any  significant 
condi tions or di seases rel evant to the di sease under study  that resolved at or prior to signing of 
inform ed consent. Thi s includes clinically  significant labora tory, ECG, or physical examinat ion 
abnorm alities noted at the screening examination, according the judgment of the invest igator. 
History  of chronic obstructive pulmo nary disease, chronic kidney and liver disease, diabetes, and 
CV com orbidi ty shoul d be docu mented. 
Medicat ion history informat ion to be obtained includes all medicat ion and any medication relevant 
to eligibilit y criteria stopped at or wi thin 24 hours pri or to si gning of informed consent.
9.1.3 Physical Examination Procedure (Including Neurology Exami
nation)
A baseline physical examinat ion (defined as the assessment before first dose of study  drug) will 
consist of the fo llowing body  systems: (1) CV system; (2) respiratory  system; (3) GI sy stem; 
(4)nervous system looking mainly for hypertonicit y, refle xes, and clo nus; and (5) other. Phy sical 
examinat ions collected as standard of care (SOC) wit hin 21 days of rando mizat ion may be used for 
study  screening purposes. If physical examinat ions are collected as SOC on the day of surgery but 
before informed cons ent, they  may be used for screening/baseline purposes as long as the results 
are assessed for eligibilit y before rando mizat ion. Any clinically significant changes from the 
baseline examinat ion will  be recorded as an AE.
A targeted neurological examinat ion looking for hypertonicit y, reflexes, and clo nus will be 
perform ed by medically  qualified personnel at screening, baseline (preinfusio n Day  1), on Day s2 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 53of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALand 5, on the last day  of study  treatm ent or early  terminati on (as applicable), and at the follow -up 
visit (14 day s post l ast dose).
During the COVID- 19 public healt h emergency , the fo llow-up visi t at 14 days (±4 day s) post l ast 
dose m ay be conducted at the clinic or via phone call (eg, collection of AEs, concomitant 
medicat ions, and monitoring), to extend flexibilit y to study  subjects. In the case of a phone call, a 
physical examinat ion (including neurology  examinati on) woul d not be collected; however, AEs 
will be assessed, including a safet y check on any  emerging clinical signs or symptoms. Subjects 
may be requested to return to the site for further safet y assessment, due to reported AEs, at the 
investigator’s discret ion. The ty pe of visit (whether clinic visit or phone call) must be recorded in 
the study  records.
9.1.4 Weight, Height, and BMI
A subject should ha ve weight and height collected as per the SOC. BMI will be derived fro m the 
subject’s height and weight. 
9.1.5 Vital Sign Procedure
Vital signs will  include bl ood pressure (systolic and diastolic) and pulse (bpm). Subjects should 
have rested for at least 5 minu tes before vital sign assessment. Vital signs collected as SOC within 
21 days of rando mizat ion may be used for study  screening purposes. If vital signs are collected as 
SOC on the day  of surgery  but before informed consent, they  may be used for screening/b aseline 
purposes as long as the results are assessed for eligibilit y before rando mizat ion.
Vital signs will  be collected at the fo llowing time points: screening, presurgery  before and at the 
end of study  drug infusi on on Day  1, on Days 2 to 10 (ie, at the end of study  drug infusio n in the 
morning and in the evening), and at the fo llow-up visit (14 days post last dose). The time window 
will be 12 hours ±4 hours. On the day o f surgery, vital signs will be mo nitored as part of the SOC. 
Clinically abnormal vita l signs will be captured as an AE as per National Cancer Inst itute Commo n 
Termino logy Cri teria for Adverse Events (NCI CTCAE) v5.0.
During the COVID- 19 public healt h emergency , the fo llow-up visi t at 14 days post l ast dose m ay 
be conducted at the clinic or via phone call (eg, collect ion of AEs, concomitant medications, and 
monitoring), to extend flexibilit y to study  subjects. In the case of a phone call, vital signs would 
not be collected; however, AEs will be assessed, including a safet y check on any emerg ing clinica l 
signs or symptom s. Subjects m ay be requested to return to the site for further safet y assessment, 
due to reported AEs, at the investigator’s discret ion. The type of visit (whether clinic visit or phone 
call) m ust be recorded in the study  recor ds.
9.1.6 Primary Efficacy Measurement
The l ength of t ime from the end of the surgery  to the occurrence of the tolerat ion of so lid foods 
(defined as first occurrence of no vomit ing or no clinically significant nausea for 1 calendar day 
after a solid meal) and ti me to first spontaneous bowel mo vement, whichever occurs later. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 54of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALIf a subject meets the primary  endpoint after midnight, the study  procedures outlined in the 
Schedule o f Study Procedures ( Appendix A)  can be completed the next day. If a subject meets the 
primary  endpoint in m orning and is di scharged l ater that day , this is considered a minor protocol 
deviat ion. Note that the exact times of first spontaneous bowel mo vement and tolerance to solid 
food shoul d be docum ented in source file and reported in the eCRF.
9.1.7 Study Surgery
The reason for surgery , the ty pe of  surgery , ASA scores, start and stop times, approximate length 
of bowel  removed (cm ), and the durati on of  the surgery will be documented.
9.1.8 Clinical Assessments
The invest igator is responsible for assessing the fo llowing on a daily  basis from  Day  1 to 
discharge:
Time to first spontaneous bowel movement and the approximate number of bowel movements 
each day .
Tolerance to fluid intake (only  until  tolerance i s achieved).
Tolerance to soft food (only  until tol erance is achieved).
Tolerance to solid food (only until tolerance is achieved).
Presence of vo miting/retching with the number of episodes in previous 24 hours, approximat e 
volume, and if bilious.
Presence and severit y of nausea measured through a numerical rat ing scale fro m 0 (no nausea) 
to 10 (worst possible nausea) as in Figure 9.a.
Figure 9.a Numerical Rating Scale
Assessment of abdo minal distensio n, including tympany if present.
Presence of flatus (only unt il first episode of flatus).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 55of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALNeed for reinsert ion of nasogastric tube in the postoperative period for NG suction.
Readiness for hospital discharge.
9.1.9 Documentation of Concurrent Medical Procedures
All procedures (eg, computed tomography  scan, biopsy , inserti on of  the NG tube, aspirat ion of 
fluid) conducted after si gning the infor med consent form and up to Day 10 of study drug 
administration are to be recorded on the eCRF. 
9.1.10 Documentation of Concomitant Medications
Concomitant medicat ion is any drug given in addit ion to the study  drug, including ant iemetics 
used for prophylaxis or t reatment of PONV, anesthetics, analgesia, or treatment for postoperative 
complicat ions. These may be prescribed by a physician or obtained by the subject over the counter. 
Concomitant medicat ion is not provided by the sponsor. All conco mitant m edicat ions received 
from the time of obtaining informed consent will be recorded. During the fo llow-up visit 14 days 
(±4 day s) post last dose, subjects will be asked whether they have taken any medication, including 
vitamin supplements, over -the-counter medicat ions, and oral herbal preparat ions, and this must be 
recorded in the eCRF. 
9.1.11 Documentation of Core ERP
Sites will docum ent that they  are f ollowing core ERP for each rando mized subject. Adherence to 
core ERP will be evaluated based on the Core ERP criteria outlined in Sect ion 6.1.
9.1.12 Procedures for Clinical Laboratory Samples
All samples will be co llected in accordance with acceptable laboratory  procedures. Results of 
clinical laboratory  assessments collected as SOC within 21 days o f rando mizat ion or HbA1c 
collected within 30 days of informed consent may be used for study screening purposes. If clinica l 
laboratory  samples are collected as SOC on the day  of surgery  but before inf ormed consent, they  
may be used for screening/baseline purposes as long as the results are assessed for eligibilit y 
before rando mizat ion. Details of these procedures and required safet y monitoring will be given in 
the site operati ons m anual.
Table 9.alists the tests that will be obtained for each laboratory  specimen.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 56of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALTable 9.a Clinical Laboratory Tests
Hematology Serum Chemistry
RBC
WBC
Hemoglobin
Hematocrit
Platelets
Prothrombin time
INR
Erythrocy te sedimentation rateALT
Albumin
Alkaline phosphatase
AST
Total bilirubin
Total protein
Creatinine
Blood urea nitrogen
Chloride
Creatine kinase
GGT
Potassium
Sodium
CRP
Other:
Serum Serum or urine
HbA1c aBeta hCG (for pregnancy, female subjects only) a
ALT, alanine aminotransferase; AST, aspartate aminotransferase ; C-reactive protein, CRP; GGT, γ -glutamyl 
transferase; HbA1c, glycosylated hemoglobin, hCG, human chorionic gonadotropin; INR, international normalized 
ratio; RBC, red blood cell; WBC, white blood cell.
aCollected at screening only. An HbA1c collected within 30 days of screening is adequate for screening purposes.
The l ocal laboratory  will perform all tests found in Table 9.a, as per the Schedule of Study  
Procedures ( Appendix A). The resul ts of laboratory  tests will  be returned to the invest igator, who 
is responsible for reviewing and filing these results.
Any clinically significant laboratory result will be captured as an AE as per the NCI CTCAE v5.0.
Treatment wit h study  drug shoul d be discont inued in subjects who develop liver test elevat ion as 
described in Section 10.1.6.4 .
9.1.13 Contraception and Pregnancy Avoidance Procedure
Animal studies for TAK -954 have dem onstrated embry otoxi city and there i s a lack of  adequate 
reproducti ve toxi city data in humans. 
Given that TAK -954 di d not exhibit genotoxic potent ial in the standard battery  of genotoxi city 
assays and the terminal disposit ion phase half -life of TAK -954, the durati on of  contracepti on for 
30 day s after the l ast dose is considered acceptable. This is in line wit hthe Clinical Trials 
Facilitat ion Group “Reco mmendat ions rel ated to contraception and pregnancy testing in clinical 
trials.”
Females of reproductive potential, as well as fertile men and their partners who are female of 
reproducti ve potenti al, m ust agree t o abstain fro m sexual intercourse or to use a highly effect ive 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 57of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALform of contraception from the t ime of giving informed consent, during the study, and for 30 days 
(females and males) following the last dose of study drug. A highly effect ive form of contracep tion 
is defined as fo llows:
Combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibit ion of ovulation:
–Oral.
–Intravaginal.
–Transdermal.
Progestogen -only hormonal contracepti on associ ated wi th inhibit ion of ovulation:
–Oral.
–Injectable.
–Implantable.
Intrauterine device.
Intrauterine hormone -releasing system.
Bilateral tubal occlusio n.
Vasectomized partner.
Sexual abst inence.
The follow ing definitions apply for contraception and pregnancy avoidance procedures:
A wo man is con sidered a woman of childbearing potential (fertile) fo llowing menarche and unt il 
beco ming postmenopausal unless permanent ly sterile. Permanent sterilizat ion methods include 
hysterectomy and bilateral oophorectomy . A postmenopausal state is defined as no me nses for 
12months wi thout an al ternat ive medical cause. 
Sterilized males should be at least 1 y ear postbilateral  vasectomy and have confirmed that they  
have obtained documentation of the absence of sperm in the ejaculate or have had bilateral 
orchi dectom y.
9.1.14 Pregnancy
If any subject is confirmed to be pregnant during the study , TAK -954 shoul d be immediately 
discontinued. In addit ion, any  pregnancies in the partner of a male subject during the study  or for 
30 day s after the l ast dose shoul d also be recorded following authori zation from the subject’s 
partner. A pregnancy notification form should be submitted within 24 hours of learning of the 
pregnancy to the contact listed in Sect ion 1.0.
If the female subject
and/or female partner of a male subject agree to the primary care physician 
being informed, the invest igator should notify the primary care physician that the female 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 58of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALsubject/female partner of the subject was participating in a clinical study  at the time she became 
pregnant and provide details o f the study  drug the subject received.
All pregnancies, including female partners of male subjects, in subjects on active study  drug will  
be followed up to f inal outcome using the pregnancy form. The study fo llow-up visits should also 
be co mpleted. The outcome, including any premature terminat ion, must be reported to the sponsor. 
An evaluat ion after the birth o f the child will also be conducted. 
9.1.15 ECG Procedure
ECG assessments collected as SOC within 21 days of rando mization may be used for study 
screening purposes. If an ECG is co llected as SOC on the day of surgery but prior to informed 
consent, i t may be used for screening/baseline purposes as long as the res ults are assessed for 
eligibilit y prior to randomizat ion. A standard 12 -lead ECG will be performed as fo llows:
Screening (Days -21 to 1) (to be reviewed by a medically qualified person). 
Day 1: pri or to and at the end of the 60 -minute IV infusio n (+20 minutes).
Day 2: At the end of the 60 -minute IV infusio n (+20 minutes) and approximately 2 hours (+20 
minutes) after the start of the 60 -minute infusio n.
Days 4, 6, 8, and 10: at the end of the 60 -minute IV infusio n (+20 minutes) on every other day 
of treatment.
Early terminat ion (as applicable).
Subjects should have rested in a supine or semisupine posit ion for at least 5 minutes before ECG. 
The same posit ion (either supine or semisupine) should be used for the same individual throughout 
the study .
When EC G, vi tal signs, and bl ood draw coincide at the same no minal time po int, the sequence o f 
procedures will be safet y ECG, vi tal signs assessment, and blood draw.
In addit ion, a 12 -lead ECG will be performed if a subject develops symptoms suggest ive of CV 
origin (eg, dizziness, chest pain, lightheadedness, chest pain, chest heaviness, palpitations, 
shortness of breath, tachy cardia). 
The invest igator (or a qualified observer at the study site) will interpret the ECG using 1 of the 
following categori es: wi thin n ormal limits, abnormal  but not clinically significant, or abnormal 
and clinically  significant. The time that a 12 -lead ECG was performed will be recorded. The 
following parameters will be recorded on the eCRF from the subject’s ECG trace: heart rate, RR 
interval , PR interval, QRS, and QT interval. The sponsor will derive QTcF. Heart -rate corrected 
QT interval will be calculated using Fridericia formula (QTcF = QT/RR1/3). Thi s same form ula 
shoul d be used for assessing eligibilit y. 
New onset or changes in EC G findings (com pared wi th baseline Day  1 preinfusi on values) are 
considered to be AEs only if they are judged to be clinically significant as per CTCAE v5.0 (ie, if 
some action or intervention is required or if the investigator judges the change to be beyo nd the 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 59of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALrange of normal physio logic fluctuation). If abnormal ECG findings are the result of pathology for 
which there is an overall diagnosis, the diagnosis should be reported appropriately as an AE 
(Secti on 10.1) .
9.1.16 Biomarker Sample Collection
Biomarkers samples will be taken for exploratory  analysis as shown in Table 9.b.
Biomarkers associ ated wi th inflammat ion, nausea, or intestinal mot ility including but not limited 
to corti sol, IL-6, IL -10, MCP -1, and CRP will be measured depending on assay feasibilit y. 
Subjects will have serum bio marker samples collected prior to and at the end of the infusio n 
(+10 minutes) and after surgery on Day 1; on Day 2, prior to and at 4 hours (+10 minutes) after the 
start of the infusio n; on Day  3 up to Day  10, a predose sam ple w ill be obtained every other day . 
Sample collect ion instructions for circulating bio markers will be explained in detail in the 
laboratory  manual to be provided to the site. The samples will be stored at site/commercial vendor, 
and analyzed as needed.
9.1.17 PK Sam ple Collection
9.1.17.1 Collection of Plasma for PK Sampling
Subjects will have PK samples collected as fo llows:
Day 1: Collect 1 sam ple pri or (wi thin 30 minutes) to the start of the infusio n, 1 sam ple at the 
end of the 60
-minute infusio n (+10 minutes), and anothe r sam ple wi thin the 1 -to 3-hour 
window after the surgery , for a total  of 3samples. 
Day 2: Collect 1 sam ple pri or (wi thin 30 minutes) to the start of the infusio n, 1 sam ple at the 
end of the 60- minute infusion (+10 minutes), and an addit ional sample with in the 3- to 5-hour 
window after the end of the infusion, for a total of 3 samples.
Day 3 up to Day 10 while on study drug: a trough (predose, within 30 minutes of the start of the 
infusio n) sample obtained every other day  starting on Day  3.
Times indicate d are relative to the start of the infusion. It is important that the date and time of each 
sample collect ion be accurately recorded on the eCRF. The date and time of start and end of 
infusio n shoul d also be accurately recorded on the eCRF. All blood sampl es, except the sample 
collected at the end of infusio n, collected outside the exact no minal t ime windows will not be 
captured as protocol deviat ions as lo ng as the date and exact time o f the sample co llection is noted 
on the source document and eCRF. Place bo PK samples will not be analyzed; therefore, the 
rando mizat ion code will be sent to the analyzing laboratory . If indicated, collected TAK
-954 
samples may  also be assayed in an exploratory  manner for m etabo lites if deemed necessary  for 
interpretati on of  the data and these data will be reported in PK list ings only.
When ECG, vital signs, and blood draw coincide at the same no minal time po int, the sequence o f 
procedures will be safet y ECG, vi tal signs assessment, and blood draw.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 60of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL9.1.18 Primary Specimen Collection
Primary specimen co llections are provided in Table 9.b.
Table 9.b Primary Specimen Collection
Specimen NamePrimary 
Specimen Description of Intended Use Sample Collection
Serum sample for circulating biomarkers Serum Biomarker measurement Mandatory
Plasma sample for TAK -954 PK Plasma PK measurements Mandatory
Abbreviations: PK, pharmacokinetic.
9.1.19 Documentation of Screen Failure
Invest igators must account for all subjects who sign informed consent.
If the subject is withdrawn at the screening visit after signing the informed consent, the 
investigator should complete the required screening eCRFs. The IRT should be co ntacted as a 
notification o f screen failure. No fo llow-up visit s are expected. 
The primary reason for screen failure is recorded in the subject source documents and eCRF using 
the following categori es:
AE.
Did not m eet incl usion criteria or di d meet exclusion criteria (specify reason).
Significant protocol  deviat ion.
Lost to follow -up.
Voluntary  withdrawal (specify  reason).
Study  terminat ion.
Other study -specific reason.
Other (specify reason).
Subject identificat ion numbers assigned to subjects who f ail screening shoul d not be reused. 
Subjects m ay be rescreened 1 time and will be given a new subject ID. 
9.1.20 Documentation of Randomization
Only subjects who meet all of the inclusio n criteria and none of the exclusio n criteria are eligible 
for randomizat ioninto the treatment phase.
If the subject is found to be not eligible for randomizat ion, the invest igator should record the 
primary  reason for failure on the applicable eCRF.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 61of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL9.1.21 Quality of Life Assessment
Qualit y of life will be assessed by  subjects completin g the fo llowing quest ionnaires at baseline, 
last day  of treatm ent, and the fo llow-up visi t at 14 days (±4 day s) post l ast dose:
SF-12.
EQ-5D.
At discharge, a printed copy o f SF-12 and EQ -5D (with pre -addressed envelopes) will be provided 
to subjects as par t of their discharge packages. If the Day 14 visit is done via phone fo llow-up, the 
study  coordinator will remind subjects to complete the qualit y of life scales on the same day as the 
follow-up phone call and co mpleted questionnaires will be mailed to the clinic.
9.2 Schedule of Observations and Procedures
The schedule for all study -related procedures for all evaluat ions is shown in Appendix A.  
Assessments should be co mpleted at the designated visit/time po int(s).
9.2.1 Post Study Care
Study  drug will not be available upon complet ion of the subject’s part icipation in the study. The 
subject should be returned to the care of a physician and standard therapies as required.
10.0 PRETREATME NT EVENTS AND ADVERS E EVENTS
10.1 Definitions
10.1.1 Pretreatment SAEs
After informed consent, but before init iation o f study  drugs, only SAEs caused by  a 
protocol -mandated intervent ion will be collected (eg, SAEs related to invasive procedures).
10.1.2 AEs
An AE is defined as any untoward m edical occurrence in a clinical invest igation subject 
administered a drug; it does not necessarily have to have a causal relat ionship with this treatment.
An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal 
laboratory  value), symptom, or disease temporally associated with the use o f a drug whether or not 
it is considered related to the drug.
10.1.3 Additional Points to Consider for AEs
An untoward finding generally may:
Indicate a new diagnosis or unexpected worsening of a pre -exist ing condit ion. (Intermittent 
events for pre -exist ing condit ions or underlying disease should not be considered AEs.)
Necessitate therapeutic intervent ion.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 62of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALRequi re an invasive diagnostic procedure.
Requi re discont inuat ion or a change in dose of study  drug or a concomitant medicat ion.
Be considered unfavorable by the invest igator for any reason.
AEs caused by a study  procedure (eg, a bruise after blood draw) should be recorded as a AE.
Diagnoses vs signs and symptoms:
Each event should be recorded to represent a single  diagnosis. Acco mpanying signs (including 
abnorm al laboratory  values or ECG findings) or symptoms should NOT be recorded as 
additional AEs. If  a diagnosis is unknown, sign(s) or symptom(s) should be recorded 
appropriately  as an AE(s).
Laboratory  values and ECG findings:
Changes in laboratory values or ECG findings are only considered to be AEs if they are judged 
to be clinically significant (ie, if so me act ion or intervent ion is required or if the invest igator
judges the change to be beyo nd the range of normal physio logic fluctuati on). A l aboratory  or 
ECG retest and/or continued monitoring of an abnormal value or finding are not considered an 
intervent ion. In addit ion, repeated or addit ional noninvasive testing for verificat ion, evaluatio n 
or monitoring of an abnormalit y is not considered an intervent ion.
If abnormal laboratory values or ECG findings are the result of pathology for which there is an 
overall diagnosis (eg, increased creat inine in renal failure), the diagnosis only  should be 
reported appropriately  as an AE.
Pre-exist ing condit ions:
Pre-exist ing condit ions (present at the time o f signing of informed consent) are considered 
concurrent medical condit ions and should NOT be recorded as AEs. If the subje ct experiences 
a worsening or complicat ion of such a concurrent medical condit ion, the worsening or 
complicat ion should be recorded appropriately an AE (worsening or complicat ion occurs after 
start of study  drug). Invest igators should ensure that the event term recorded captures the 
change in the condit ion (eg, “worsening of…”).
If a subject has a pre -exist ing episodic concurrent medical condit ion (eg, asthma, epilepsy) any 
occurrence of an episode should only be captured as a AE if the condit ion beco mes more 
frequent, serious, or severe in nature. Invest igators should ensure that the AE term recorded 
captures the change in the condit ion from baseline (eg “worsening of…”).
If a subject has a degenerat ive concurrent medical condit ion (eg, cataracts, rheumatoi d 
arthri tis), worsening of the condit ion should only be recorded as a AE if occurring to a greater 
extent to that which would be expected. Invest igators should ensure that the AE term recorded 
captures the change in the condit ion (eg, “worsening of…”).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 63of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALWorsening of AEs:
If the subject experiences a worsening or complicatio n of an AE after any change in study drug, 
the worsening or complication should be recorded as a new AE. Investigators should ensure 
that the AE term recorded captures the change in the co ndition (eg, “worsening of…”).
Changes in intensit y of AEs:
If the subject experiences changes in intensit y of an AE, the event should be captured once 
with the m aximum  intensity recorded.
Prepl anned procedures (surgeries or intervent ions):
Prepl anned proc edures (surgeries or therapies) that were scheduled prior to signing of 
inform ed consent are not considered AEs. However, if a preplanned procedure is performed 
early (eg, as an emergency) due to a worsening of the pre -exist ing condit ion, the worsening o f 
the condit ion should be recorded as an AE. Complications result ing fro m any planned surgery 
shoul d be reported as AEs.
Elect ive surgeries or procedures:
Elect ive procedures performed where there is no change in the subject’s medical condit ion 
shoul d not be recorded as AEs, but should be documented in the subject’s source documents. 
Com plicat ions result ing from an elect ive surgery should be reported as AEs.
Insufficient clinical response (lack of efficacy):
Insufficient clinical response, efficacy, or pharmacologic act ion should NOT be recorded as an 
AE. The invest igator must make the dist inction between exacerbation of pre -exist ing illness 
and lack of therapeutic efficacy.
Overdose:
Cases of overdose with any  medicati on wi thout m anifested si de effects are NOT considered 
AEs, but instead will be documented on an Overdose page of the eCRF. Any manifested side 
effects will be considered AEs and will be recorded on the AE page of the eCRF.
10.1.4 SAEs
An SAE is defined as any untoward medical occurrence:
1.Results i n DEATH.
2.Is LIFE THREATENING.
The term “life threatening” refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have caused death 
if it were m ore severe.
3.Requi res inpa tient HOSPITALIZATION or prolongation of exist ing hospitalizat ion.
4. Results in persistent or significant DISABILITY/INCAPACITY.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 64of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL5.Leads to a CONGENITAL ANOMALY/BIRTH DEFECT.
6.Is an IMPORTANT MEDICAL EVENT based on the opinio n of eit her the invest igator or 
spon sor that sati sfies any of the fo llowing:
May require intervent ion to prevent items 1 through 5 above.
May expose the subject to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospitalization.
10.1.5 Severity of AE s
All AEs, including clinically  significant treatm ent-emergent laboratory  abnorm alities, will be 
graded according to CTCAE v5.0. AEs not listed by the NCI CTCAE will be graded displayed in 
Table 10.a.
Table 10.a NCI CTCAE
Grade Description
1 Mild; asy mptomatic or mild symptoms; clinical or diagnostic observations only; intervention not 
indicated.
2 Moderate; minimal, local, or noninvasive intervention indicated; limiting age -appropriate 
instrumental ADL a.
3 Severe or medically significant but not immediately life -threatening; hospitalization or prolongation 
of hospitalization indicated; disabling; limiting self -care ADL.
4 Life-threatening consequences; urgent intervention indicated.
5 Fatal AE; an event that results in the death of the subject.
Abbreviations: ADL: activities of daily living; AE, adverse event; NCICAE, National Cancer Institute Common Terminology 
Criteria for Adverse Events.
aInstrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, 
etc.
10.1.6 Management of Specific AEs
10.1.6.1 CV Disorders
CV Events:
Subjects with clinically signific ant ECG abnorm alities indicat ive of acute cardiac instabilit y or 
acute my ocardial  ischemia or infarct ion, as determined by  the invest igator at screening will be 
excluded fro m the study . 
Suspected CV events that include ischemic heart disease, cerebrovascu lar accident (eg, transient 
ischemic attack and stroke), venous or arterial thromboembo lic events, and heart failure, should be 
reported as an AESI to the sponsor within 24 hours irrespective of the seriousness. These events 
will be adjudicated by  a cardi ovascular endpo int committee (CEC).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 65of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALQT prolongation
Subjects with >5 beats of nonsustained VT at a rate >120 bpm or have QTcF ≥450 msec or other 
factors that increase the risk of QT prolongat ion or arrhythmic events at screening will be excluded 
from the study. Subjects with bundle branch block and a prolonged QTcF should be reviewed by a 
cardi ologist for potenti al inclusio n.
Any QT prolongat ion event assessed as Grade 2 or worse (QTcF longer than 480 msec), 
irrespect ive of the seriousness, should be reporte d as an AESI to the sponsor within 24 hours and 
managed according to the guidelines below. 
Table 10.b Management of QT Prolongation by NCI CTCAE Grade
NCI CTCAE Grade Management
Grade 2 
(QTcF a>480 and ≤500 msec) Levels of electrolytes (potassium, calcium, and magnesium) should be 
checked and supplementation given to correct any values outside the 
normal range.
Concomitant therapies should be reviewed and adjusted as appropriate 
for medications with known QT prolonging effects.
If no other cause is identified and the investigator believes it is 
appropriate, particularly if QTcF remains elevated (after the above 
measures have been implemented, or as determined by the 
investigator), study treatment may be interrupted for 1 dose for up to 2 
days, and an ECG should be rechecked regularly. If QTcF remains 
elevated, study treatment will be discontinued.
If QTcF has recovered or improved <450 msec and the investigator 
believes it is safe to do so, rechal lenge with study treatment should be 
considered after discussion with the medical monitor.
ECGs should be conducted at least weekly (eg, at every scheduled 
visit) for 2 weeks following QTcF reduction ≤480 msec.
Discontinue treatment with study drug if the subject develops a 
second episode of Grade 2 QT prolongation.
Grade 3 
(QTcF a>500 msec) or >60 msec change 
from baseline
OR
Grade 4 
Torsades de pointes or polymorphic VT or 
signs/symptoms of serious arrhythmia Subjects should have continuous cardiac m onitoring and be discharged 
only after review by a cardiologist. 
Treatment with study treatment should be permanently 
discontinued. 
Abbreviations: ECG, electrocardiogram; NCI CTCAE, National Cancer Institute Common Terminology Criteria for 
Adverse Events; QTcF, QT interval with Fridericia correction method; VT, ventricular tachycardia.
a Heart rate -corrected QT interval will be calculated using Fridericia’s formula (QTcF=QT/RR1/3).
AV Dissociation/Heart Block
Patients wi th AV bl ock other than fi rst degree heart block will be excluded fro m the study .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 66of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALTreatment with study  drug shoul d be discont inued with the occurrence of any second -or 
third-degree heart block and these events should be reported to the sponsor as AESI within 24 
hours.
Treatments wit h study drug may be continued in second -degree heart block Mobitz I (Wenckebach) 
after m edical m onitor revi ew.
SVT
Any SVT assessed as Grade 2 or worse irrespect ive of the seriousness should be reported as an 
AESI to the sponsor within 24 hours and managed according to the fo llowing gui delines.
Table 10.c Management of SVT by NCI CTCAE Grade
NCI CTCAE Grade Management
Grade 2: Symptomatic; nonurgent medical 
interventio n indicated
Or G3: Urgent medical intervention 
indicatedRule out other etiology such as pain, hypovolemia, or pyrexia.
If no other cause is found and SVT is persistent: study drug should be 
interrupted for 1 to 2 days.
Treatment can be restarted if the patient is hemodynamically stable 
with careful monitoring.
G4: Life -threatening consequences; urgent 
interventio n indicatedStudy drug should be discontinued and the patient managed as per local 
guidelines. 
Abbreviations: NCI CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events; SVT, 
supraventricular tachycardia.
Hypotension/Orthostatic Hypotension
If the subject has orthostatic hypotensio n prior to dosing, the treatment should be delayed and the 
case should be discussed with the medical mo nitor. 
If any subject develops Grade 3 hypotension or orthostatic hypotension, the medical mo nitor 
shoul d be contacted and the hypotensive event should be investigated and managed as per 
institutional guidelines.
For Grade 4 hy potension, treatm ent wi th study  drug shoul dbe di scontinued. 
10.1.6.2 Serotonin Syndrome
Neurol ogical examinat ions looking for hypertonicity , reflexes, and clo nus will be performed at 
screening and during treatment with study  drug as per the Schedule of Study  Procedures 
(Appendix A). 
Treatment with study  drug shoul d be discont inued if a subject develops any of the fo llowing 
clinical features (Hunter’s criteria):
Spontaneous clonus.
Inducible clonus PLUS agitation or dia phoresi s.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 67of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALOcul ar clonus PLUS agitation or diaphoresis.
Trem or PLUS hy perreflexia.
Hypertoni a PLUS tem perature above 38ºC PLUS ocular clonus or inducible clo nus.
In case of a suspected serotonin syndro me, treatment with TAK -954 and/or other potential 
seroto ninergic drugs will be immediately interrupted and other supportive and therapeut ic 
measures will be init iated as clinically  indicated. Any  suspected case of serotonin syndrome will 
be reported to the sponsor as a serious AESI within 24 hours.
10.1.6.3 Diarrhea
AEs of diarrhea (new onset or change from baseline) should be invest igated for underlying 
etiology and graded for severit y as per the NCI CTCAE grading system, as follows:
Grade 1: Increase of <4 stools per day over baseline; mild increase in ostomy output co mpared 
to baseline.
Grade 2: Increase of 4 to 6 stools per day  over baseline; m oderate increase in ostomy  output 
compared to baseline.
Grade 3: Increase of ≥7 stools per day  over baseline; incontinence; hospitalizat ion indicated; 
severe increase in ostomy output compared to baseline; limit ing self -care of act ivities of daily 
living. 
Grade 4: Life -threatening consequences; urgent interven tion indicated.
Grade 5: Death.
Diarrhea Grade 3 and above should be reported as AESI to the sponsor within 24 hours.
10.1.6.4 Abnormal Liver Tests
Treatment with study  drug shoul d be discont inued in subjects who develop ALT and/or 
AST >3 ×ULN concurrently wit h total bilirubin >2 × ULN while on treatment with study  drug. 
These findings should be reported to the sponsor as a serious AESI. The invest igator must contact 
the medical mo nitor for discussio n of the relevant subject details and possible alternat ive 
etiologies such as acute viral hepatit is, other acute liver disease, or medical history/concurrent 
medical condit ions. In addit ion, the invest igator should contact the medical monitor for any 
increase in liver tests without clear etio logy.
10.1.6.5 AESI
An AESI (serious o r non -serious) is 1 of scientific and medical concern specific to the compound 
or program , for whi ch ongoing m onitoring and these events must be reported within 24 hours of 
awareness to the sponsor.
The fo llowing events will be reported as AESI:
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 68of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALSuspected CV events (ischemic heart disease, cerebrovascular accident [eg, transient ischemic 
attack and stroke], venous or arterial thromboembolic events, and heart failure).
QT prol ongat ion G2 or above.
2nd or 3rd degree heart block.
SVT G2 or above with heart rat e over 130 bpm.
Suspected serotonin syndro me.
Diarrhea Grade 3 or higher.
Liver test elevat ions as defined in Sect ion 10.1.6.4 .
10.1.7 Causality of AEs
The rel ationship of each AE to study  drug(s) will be assessed using the fo llowing categori es:
Related: An AE that follows a reasonable temporal sequence from administration of a drug (including the 
course after withdrawal of the drug), or for which possible involvement of th e drug cannot be 
ruled out , although factors other than the drug, such as underlying diseases, complications, 
concomitant medications, and concurrent treatments, may also be responsible.
Not Related: An AE that does not follow a reasonable temporal sequence from administration of a drug and/o r 
that can reasonably be explained by other factors, such as underlying diseases, complications, 
concomitant medications, and concurrent treatments.
10.1.8 Relationship to Study Procedures
Relationship (causalit y) to study procedures should be determined for all AEs.
The relationship should be assessed as Related if the investigator considers that there is reasonable 
possibilit y that an event is due to a study procedure. Otherwise, the relationship should be assessed 
asNot Rel ated. 
10.1.9 Start Date
The start date of the AE/SAE is the date that the first signs/symptoms were noted by  the subject 
and/or invest igator.
10.1.10 Stop Date 
The stop date of the AE/SAE is the date at which the subject recovered, the event resolved but with 
sequelae or the subject died.
10.1.11 Frequency 
Episodi c AEs (eg, vomit ing) or those which occur repeatedly over a period of consecut ive days are 
intermittent. All other events are continuous.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 69of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL10.1.12 Action Concerning Study Drug 
Dose interrupted –the dose was interrupt ed due to the particular AE. Subjects will discont inue 
treatm ent wi th study  drug if the interruption is for 2 or more doses.
Drug withdrawn –a study  drug i s stopped due to the particular AE.
Dose not changed –the particular AE did not require stopping a study  drug.
Unknown –only to be used if it has not been possible to determine what action has been taken.
Not applicable –a study  drug was stopped for a reason other than the particular AE eg, the 
study  has been terminated, the subject died, dosing with study  drug was already stopped before 
the onset of the AE.
10.1.13 Outcome
Recovered/reso lved – Subject returned to first assessment status with respect to the AE.
Recovering/resolving –the intensit y is lowered by  1 or m ore stages: the diagnosis or 
signs/symptom shas almost disappeared; the abnormal laboratory  value improved, but has not 
returned to the normal range or to baseline; the subject died from a cause other than the 
particular AE wi th the condi tion rem aining “recovering/resolving.”
Not recovered/not reso lved –there is no change in the diagnosis, signs or symptoms; the 
intensity of the di agnosis, signs/symptoms or laboratory  value on the l ast day  of the observed 
study  period has got worse than when it started; is an irreversible congenital anomaly; the 
subject di ed from another cause with the particular AE state remaining “Not recovered/not 
resolved.”
Reso lved with sequelae –the subject recovered from an acute AE but was left with 
perm anent/si gnificant impairment (eg, recovered from a CV accident but with some persist ing 
paresis).
Fatal  –the AEs which are considered as the cause of death. 
Unknown –the course of the AE cannot be fo llowed up due to hospi tal change or residence 
change at the end of the subject’s participation in the study .
10.2 Procedures
10.2.1 Collection and Reporting of AEs
10.2.1.1 AE Collection Period
Collect ion of SAEs caused by a protocol -mandated intervent ion will commence from the time the 
subject signs the informed consent to participate in the study and continue unt il the subject is first 
administere d study  drug (Day  1) or until screen failure. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 70of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALCollect ion of AEs and SAEs (treatment -emergent) will co mmence fro m the time that the subject is 
first administered study  drug (Day  1). Routine co llection of AEs and SAEs will cont inue unt il the 
final fo llow-upvisit (90 day s post last dose).
10.2.1.2 AE Reporting
At each study  visit, the investi gator will assess whether any  subjective AEs have occurred. A 
neutral  quest ion, such as “How have you been feeling since your last visit ?” may be asked. 
Subjects m ay report AEs occurri ng at any  other time during the study . 
All subjects experiencing AEs or SAEs, whether considered associated with the use of the study  
drug or not, must be monitored until the symptoms subside and any clinically relevant changes in 
laboratory  values have returned to baseline or until there is a sat isfactory  explanat ion for the 
changes observed. All AEs will be documented in the AE page of the eCRF, whether or not the 
investigator concludes that the event is related to the drug treatment. The fo llowing informat ion 
will be documented for each event:
1.Event term .
2.Start and stop date.
3.Frequency.
4.Severit y as per NCI CTCAE.
5.Invest igator’s opinio n of the causal relat ionship between the event and administration of study 
drugs (related or not related).
6.Invest igator’s opinio n of the causal relat ionship to study  procedure(s), including the details of 
the suspected procedure.
7.Action concerning study  drug.
8.Outcom e of event.
9.Seriousness.
10.2.1.3 AESI
AESI have to be recorded as AEs in the eCRF. An evaluat ion form along wi th all other required 
docum entati on m ust be submitted to the sponsor.
10.2.2 Collection and Reporting of SAEs
When an SAE occurs through the AE collection period it should be reported according to the 
following procedure:
As soon as an SAE is entered into the electr onic data capture system, an alert is sent to the attention 
of the contact listed in Sect ion 1.1.
The informat ion shoul d be com pleted as fully  as possible but contain, at a minimum:
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 71of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALA short descript ion of the event and the reason why  the event i s categori zed as serious.
Subject identificat ion number.
Invest igator’s name.
Nam e of the study  drug(s).
Causalit y assessment.
The SAE eCRF should be transmitted within 2 4 hours of first onset or notification o f the event. 
However, as a back -up, if required, the SAE form should be co mpleted and reported to the 
attenti on of  the contact listed in Section 1.1.
Any SAE spontaneously reported to the invest igator fo llowing the AE collect ion period should be 
reported to the sponsor if considered related to study  parti cipat ion.
10.3 Follow -up of SAEs
If informat ion not available a t the time of the first report becomes available at a later date, the 
investigator should complete a fo llow
-up SAE form  or provi de other wri tten docum entati on and 
fax it immediately wit hin 24 hours of receipt . Copies of any relevant data from the hospital notes 
(eg, ECGs, laboratory  tests, di scharge summary, postmortem results) should be sent to the 
addressee, if requested.
All SAEs should be fo llowed up unt il reso lution or perm anent outcome of the event. The timelines 
and procedure for follow -up reports ar e the same as those for the init ial report.
10.3.1 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities
The sponsor will be responsible for reporting all suspected unexpected serious adverse react ions 
(SUSARs) and any other applicable SAEs to regulatory  authori ties, invest igators, and IRBs or 
IECs, as applicable, in accordance with nat ional regulat ions in the countries where the study  is 
conducted. Relat ive to the first awareness of the event by/or further provisio n to the sponsor or 
sponsor ’s designee, SUSARs will be submitted to the regulatory authorit ies as expedited report 
within 7 days for fatal and life -threatening events and 15 days for other serious events, unless 
otherwi se requi red by  national regulat ions. The sponsor will also prepare an expedited report for 
other safet y issues where these might materially alt er the current benefit -risk assessment of a study 
drug/sponsor supplied drug or that would be sufficient to consider changes in the study 
drug/sponsor supplied drug administrati on or in the overall conduct of the trial. The study site also 
will forward a copy  of all expedited reports to his or her IRB or IEC .
11.0 STUDY- SPECIFIC COMMITTEES
11.1 Independent CEC
An independent CEC consist ing of 2 CV experts and 1 neuro logist will review and adjudicate all 
suspected CV events in a blinded fashio n to determine if the reported event meets the criteria for 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 72of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALmajor adverse cardiac event. Details of the independent CEC, including meet ing frequency , will 
be captured in a charter prior to the start of the trial.
11.2 Internal Monitoring Committee
An IMC within Takeda composed of a senior clinician, a senior statist ician, and a senior 
pharmacovigilance physician not invo lved in the study  will perform  ongoing reviews of the 
serious AEs, conduct periodic schedu led reviews of safet y, and conduct reviews of IA results. The 
IMC i s responsible for making recommendat ions for changes to the study  after the IA, if 
appropriate. 
Details o f the IMC, including meet ing frequency, will be captured in a charter prior to the start of 
the study .
12.0 DATA HANDLING AND RE CORDKEEPING
The full details of procedures for data handling will be documented in the Data Management Plan. 
AEs, m edical history , and concurrent medical condit ions will be coded using the Medical 
Dictionary for Regulatory  Activities (MedDRA). Drugs will be coded using the World Health 
Organizat ion (WHO) Drug Dict ionary.
12.1 CRFs (Electronic and Paper)
Com pleted eCRFs are required for each subject who signs an informed consent.
The sponsor or its designee will supply study  sites wi th access to eCRFs. The sponsor will make 
arrangements to train appropriate site staff in the use of the eCRF. These forms are used to transmit  
the informat ion collected in the performance of this study to the sponsor and regulatory authoriti es. 
eCRFs must be completed in English. Data are transcribed directly  onto eCRFs.
After complet ion of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by the sponsor’s 
personnel (or designees) and will be answered by the site. 
Correcti ons are recorded i n an audit trail that captures the old informat ion, the new informat ion, 
ident ificat ion of the person making the correction, the date the correcti on was made, and the reason 
for change. Reasons for si gnificant correcti ons shoul d addi tionally be included. 
The principal invest igator must review the eCRFs for completeness and accuracy and must e-sign 
the appropriate eCRFs as indicated. Furthermore, th e invest igator must retain full responsibilit y 
for the accuracy  and authent icity of all data entered on the eCRFs .
After the lock of  the study database, any  change of, m odificati on of  or addi tion to the data on the 
eCRFs should be made by the invest igator with use of change and modificat ion records of the 
eCRFs. The principal invest igator must review the data change for completeness and accuracy, 
and must sign, or sign and seal, and date.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 73of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALeCRFs will be reviewed for completeness and acceptabilit y during peri odic monitoring by the 
sponsor or its designee. The sponsor or its designee will be permitted to review the subject’s 
medical and hospital records pertinent to the study  to ensure accuracy  of the eCRFs. The 
completed eCRFs are the sole property  of the spon sor and should not be made available in any 
form to thi rd parti es, except for authorized representatives o f appropri ate governmental healt h or 
regul atory  authori ties, wi thout wri tten permissio n of the sponsor. 
12.2 Record Retention
The invest igator agrees to k eep the records stipulated in Section 12.1 and those documents that 
include (but are not limited to) the study -specific documents, the ident ificat ion log of all 
participating subjects, medical records, temporary media such as thermal sensit ive paper, source 
worksheets, all original signed and dated informed consent forms, subject authorizat ion forms 
regarding the use of personal healt h information (if separate from th e inform ed consent forms), 
and detailed records of drug disposit ion to enable evaluat ions or audits fro m regulatory  authorit ies, 
the sponsor or its designees. Any source documentation printed on degradable thermal sensit ive 
paper should be photocopied by  the site and filed with the original in the subject’s chart to ensure 
long term  legibilit y. Furtherm ore, In ternati onal Conference on Harmonisat ion (ICH) E6 Section 
4.9.5 requires the invest igator to retain essent ial documents specified in ICH E6 (Secti on8)until at 
least 2 years after the last approval of a market ing applicat ion for a specified drug indicat ion being 
investigated or, if an applicat ion is not approved, unt il at least 2 years after the invest igation is 
discontinued and regulatory  authori ties are notified. In addit ion, ICH E6 Secti on4.9.5 states that 
the study  records should be retained unt il an amount of time specified by applicable regulatory 
requi rements or for a time specified in the study  site agreem ent between the investigator and 
sponsor .
Refer to the study  site agreement for the sponsor’s requirements on record retention. The 
investigator should contact and receive written approval fro m the sponsor before disposing of any 
such documents.
13.0 STATISTICAL METHODS
13.1 Statistical and Analytical Pla ns
A stati stical analysis plan (SAP) will be prepared and finalized prior to unblinding of subject’s 
treatm ent assi gnment. Thi s docum ent will provide further details regarding the definit ion of 
analysis variables and analysis methodology  to address all stu dy object ives.
A blinded data review will be conducted prior to unblinding of subject’s treatment assignment. 
This review will assess the accuracy and completeness of the study database, subject evaluabilit y, 
and appropriateness o f the planned statist ical methods.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 74of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL13.1.1 Analysis Sets
The full analysis set (FAS) will include all subjects who were randomized and received at least 
1dose of study  drug, and have at least 1 postbaseline value for assessment of efficacy . In FAS 
efficacy  summaries, subjects will be analyzed by  the treatment t o which they  were randomized. 
The per -protocol set (PPS) will include all FAS subjects who had no major protocol deviat ion that 
could confound the interpretation of the primary analyses based on the FAS. The major protocol 
deviat ions that lead to a subjec t’s exclusio n from the FAS to form the PPS will be specified in the 
SAP. The PPS will be used to perform sensit ivity analysis for the efficacy  endpoints.
The safet y set will include all subjects who were rando mized and received at least 1 dose of 
doubl e-blind study  medicat ion. In safety  summaries, subjects will be analyzed according to the 
treatm ent they  received.
13.1.2 Analysis of Demographics and Other Baseline Characteristics
Dem ographic and baseline characteristics will be summarized by each treatment group a nd overall. 
Summary  statistics (N, m ean, SD, median, minimum, and maximum) will be generated for 
continuous variables (eg, age and weight) and the number and percentage of subjects within each 
category  will be presented for categorical variables (eg, sex, ethnicit y, and race). Individual 
subject demographic and baseline characterist ics data will be listed.
13.1.3 Efficacy Analysis
The primary efficacy endpo int is time fro m the end of surgery to resolut ion of upper and lower GI 
funct ion (ie, time to fi rst tolerance of solid food [defined as first occurrence of no vo miting or no 
clinically significant nausea for 1 calendar day after a solid meal] and first spontaneous bowel 
movement, whichever occurs later) up to Day  10 postsurgery . 
The primary  endpoint will be anal yzed using the Cox proportional hazard model with treatment 
group as a single covariate, with Efron’s method of t ie handling, stratified by rando mizat ion 
stratificat ion factor. Hazard ratios between TAK -954 doses/regimens and placebo and their 90% 
CIs base d on the Cox m odel will be presented. P -values for the comparisons of TAK -954 
doses/regimens and placebo will be calculated using Wald chi -square test based on the Cox model 
and presented. Median time to resolut ion of upper and lower GI funct ion will be es timated by  
Kaplan -Meier survival analysis. The hazard ratios and median time differences between TAK -954 
doses/regimens and placebo will be used to express the magnitude of treatment effects. The 
statist ical tests will be 1-sided comparing TAK- 954 doses/re gimens to pl acebo. As a sensit ivity 
analysis, the primary endpoint will be analyzed using the same method above based on PPS. 
In the final analyses of efficacy  endpoints, for the 2 discont inued treatment arms, only the 
summary statist ics (n, m ean, SD, m edian, minimum, and maximum for continuous endpo ints; 
number and percentage of subjects for categorical data; the number and percentages o f events and 
censoring, median, minimum, and maximum for time to event endpo int) will be provided; for the 
remaining tre atment groups after IA, the inferent ial statistics (point estimates of interest and 90% 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 75of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALCIs and 1 -sided p-values) for each treatment group and the TAK- 954 doses/regimens in 
comparison wi th placebo will  be provi de al ong wi th summary  statist ics.
The secondar y endpoints time to tolerance of so lid food from the end of surgery, time to first 
spontaneous bowel movement from the end of surgery, time fro m the end of surgery unt il ready for 
discharge, time fro m the end of surgery  until the discharge order is written , time fro m the end of 
surgery  to discharge fro m ho spital, and t ime fro m the end o f surgery to first flatus will be analyzed 
using similar statist ical methods described for the primary  efficacy  analysis. 
The comparisons of TAK -954 dose levels and placebo in percent of subjects with POGD ≥5 days 
and the percent of subjects requiring insertion of NG tube postsurgery  will be based on the 
Miettinen and Nurminen’s method stratified by randomizat ion stratificat ion factor f or risk 
difference.
13.1.4 PK Analysis
No formal noncom partm ental  PK analyses will be performed on concentration -time data. The 
observed plasma concentrations of TAK- 954 will be summarized by dose/regimen at study  
scheduled day/t ime point where appropriate. Individual concentration -time data for TAK -954 and 
its metabo lites will be included in list ings. 
A populat ion PK analysis may be conducted and a more detailed description of these analyses will 
be given in a separate analysis plan. The results from these analyses will not be included in the 
clinica l study  report and will be a standalo ne report.
13.1.5 Safety Analysis
AEs will be summarized using the safet y analysis set. 
All AEs will be coded using MedDRA. Data will be summarized using preferred term and primary 
system  organ cl ass. The definit ion of treatm ent-emergent AEs will be provided in the SAP. AEs 
will be coded using MedDRA and will be summarized by system organ class and preferred term in 
the core treatment period and ent ire study .
AEs that were reported more than once by a subject during the same p eriod will be counted only  
once for that subject and period at the maximum severit y.
Clinical Evaluations:
Absolute values and changes from screening/baseline in clinical safet y laboratory  tests, vital signs, 
ECG parameters, and weight will be summarized f or each treatment group using descript ive 
summary statist ics. Values outside normal ranges and potentially clinically significant values will 
be flagged and tabulated.
13.2 IA and Criteria for Early Termination
The first IA will be conducted after approximately 125 subjects (25 per arm) have completed or 
withdrawn from  the study . The second IA is removed. Following the IA, bayesian approach for 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 76of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALdecisio n making will be implemented for the potential study  modificat ion including fut ility, 
regimen decisio n, and samp le size adjust ment. 
The IMC will review the IA results and make recommendat ions for changes to the study , if 
appropriate. All members of the study  team  and the invest igative team will remain blinded to 
treatm ent arm  assignment and treatm ent arm  resul ts un til the com pletion of the study .
13.3 Determination of Sample Size
Assuming 80% of subjects will have reso lution of POGD at the end of study  in the pl acebo group 
and 92.5% of subjects will have resolut ion of POGD at the end of study  in the act ive TAK -954 
doses, a total of approximately 300 subjects (100 per treatment group) will provide 80% power 
with a 0.05 2 -sided significance level under Protocol Amendment 4.
In order to mit igate the statist ical, clinical, and operational risks to this study in light of the 
COVID -19 pandemic, the probabilit y of success of the study  is re-estimated by blinded 
assessments using efficacy assumpt ions of Protocol Amendment 4. Specifically, by the remo val of 
the second IA per this amendment and changing the statist ical significance level fro m 2-sided 5% 
to 1-sided 5%, the result ing sample size is an overall total of 50 subjects for each remaining arm 
(Figure 6.b). Under these revised assumpt ions an d the dropping of 2 arms, an overall total of 
approximately  180 subjects for the study will provide approximately 80% probabilit y, for at least 1 
remaining TAK -954 treatm ent arm , that TAK -954 is superior to placebo in t ime to resolut ion of 
upper and lower GI funct ion at a 1 -sided 5% significance level for the final analysis.
14.0 QUALITY CONTROL AND QUALITY ASSURANCE
14.1 Study -Site Monitoring Visits
Moni toring visit s will be made periodically  during the study  to ensure that all aspects of the 
protocol  are fo llowed. Moni toring may  be done remotely  where all owed by  local regulati ons and 
ethics approval s.Source docum ents will  be reviewed for verificat ion of data recorded on the 
eCRFs. Source documents are defined as original documents, data, and records. The invest igator 
and the study  site guarantee access to source documents by  the sponsor or i ts desi gnee (contract 
research organizat ion) and by  the IRB or IEC.
All aspects of the study and its documentation will be subject to review by the sponsor or sponsor’s 
designee (as long as blinding is not jeopardized), including but not limited to the Investigator’s 
Binder, study  drug, subject m edical records, informed consent documentation, documentation of 
subject authorizat ion to use personal healt h information (if separate fr om the inform ed consent 
form), and review of eCRFs and associated source documents. It is important that the invest igator 
and other study  personnel are available during the mo nitoring visits and that sufficient time is 
devoted to the process.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 77of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL14.2 Protocol Devi ations
The invest igator should not deviate fro m the protocol , except where necessary  to eliminate an 
immediate hazard to study subjects. Should other unexpected circumstances arise that will require 
deviat ion from protocol -specified procedures, the investi gator shoul d consul t with the sponsor or 
designee (and IRB or IEC, as required) to determine the appropriate course of action. There will be 
no exempt ions (a prospectively approved deviat ion) from the inclusio n or exclusio n criteria.
The site should docume nt all protocol deviat ions in the subject’s source documents. In the event of 
a significant devi ation, the si te shoul d notify  the sponsor or i ts desi gnee (and IRB or EC, as 
requi red). Si gnificant devi ations include, but are not limited to, those that invo lve fraud or 
misconduct, increase the health risk to the subject, or confound interpretation of primary study 
assessment. 
14.3 Quality Assurance Audits and Regulatory Agency Inspections
The study  site also m ay be subject to qualit y assurance audi ts by  the spons or or desi gnees. In this 
circumstance, the sponsor -designated audi tor will  contact the si te in advance to arrange an 
auditing visit. The auditor may ask to visit the facilit ies where laboratory  samples are collected, 
where the study  drug is stored and prep ared, and any other facilit y used during the study . In 
addition, there is the possibilit y that this study may be inspected by regulatory agencies, including 
those of foreign governments (eg, FDA, the United Kingdo m Medicines and Healt hcare products 
Regulat ory Agency, the Pharmaceuticals and Medical Devices Agency  of Japan). If the study  site 
is contacted for an inspect ion by a regulatory  body, the sponsor should be notified immediately . 
The invest igator and study sites guarantee access for qualit y assurance auditors to all study  
docum ents as described in Sect ion 14.1.
15.0 ETHICAL ASPECTS OF T HE STUDY
This study  will be conducted wi th the highest respect for the individua l participants (i e, subjects) 
according to the protocol, the ethical principles that have their origin in the Declarat ion of Helsinki, 
and the ICH Harmonised Tripartite Guideline for GCP. Each invest igator will conduct the study 
according to applicable loc al or regi onal regulatory  requirements and align his or her conduct in 
accordance with the “Responsibilit ies of the Investigator” that are listed in Appendix B.  The 
principles of Helsinki are addressed through the protocol and through appendices containing 
requi rements for informed consent and invest igator responsibilities.
15.1 IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable state and federal/local requirements 
of each participat ing regio n. The sponsor or designee will require documentation noting all names 
and tit les of members who make up the respective IRB or IEC. If any member of the IRB or IEC 
has di rect parti cipat ion in this study , written notification regarding his or her abstinence fro m 
voting must also be obtained. Those Americas sites unwilling to provide names and tit les of all 
members due to privacy  and conflict of interest concerns should instead provide a Federal Wide 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 78of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALAssur ance Number or comparable number assigned by the Department of Health and Human 
Services.
The sponsor or designee will supply relevant documents for submissio n to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the Invest igator’s Brochure, a copy  of 
the informed consent form, and, if applicable, subject recruit ment materials and/or advertisements 
and other documents required by all applicable laws and regulations, must be submitted to a 
central  or local IRB or IEC for approv al. The IRB’s or IEC’s written approval of the protocol and 
subject informed consent must be obtained and submitted to the sponsor or designee before 
commencement of the study  (ie, before shipment of the sponsor -supplied drug or study specific 
screening ac tivity). The IRB or IEC approval must refer to the study  by exact protocol tit le, 
number, and versio n date; ident ify versio ns of other documents (eg, informed consent form) 
reviewed; and state the approval date. The sponsor will notify site once the sponso r has confirmed 
the adequacy  of site regulatory  docum entati on. Until  the si te receives notificati on no protocol  
activit ies, including screening may occur.
Study  sites m ust adhere to all requirements st ipulated by their respect ive IRB or IEC. This may 
inclu de notificat ion to the IRB or IEC regarding protocol amendments, updates to the informed 
consent form, recruit ment materials intended for viewing by  subjects, l ocal safety reporting 
requi rements, reports and updates regarding the ongoing review of the stud y at intervals specified 
by the respective IRB or IEC, and submissio n of the invest igator’s final status report to IRB or IEC. 
All IRB and IEC approvals and relevant documentation for these items must be provided to the 
sponsor or its designee.
Subject rei mbursements should not exert undue influence for participation. Payments to subjects 
must be approved by the IRB or IEC and sponsor.
15.2 Subject Information, Informed Consent, and Subject Authorization
Written consent documents will embody  the elements of info rmed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The informed consent form, subject authorizat ion form (if 
applicable), and subject informat ion sheet (if applicable) describe the planned and permitted uses, 
transfers, and disclo sures of the subject’s personal and personal healt h informat ion for purposes of 
conducting the study. The informed consent form and the subject informat ion sheet (if applicable)
further explain the nature of the study, its object ives, and potential risks and benefit s, as well as the 
date informed consent is given. The informed consent form will detail the requirements of the 
participant and the fact that he or she is free to with draw at any  time wi thout giving a reason and 
without prej udice to hi s or her further m edical care.
The invest igator is responsible for the preparation, content, and IRB or IEC approval of the 
inform ed consent form  and if applicable, the subject authorizati on form. The inform ed consent 
form, subject authorizat ion form (if applicable), and subject information sheet (if applicable) must 
be approved by both the IRB or IEC and the sponsor prior to use.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 79of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALThe informed consent form, subject authorizat ion form  (if ap plicable), and subject informat ion 
sheet (if applicable) must be written in a language fully co mprehensible to the prospective subject. 
It is the responsibilit y of the invest igator to explain the detailed elements of the informed consent 
form, subject auth orization form (if applicable), and subject informat ion sheet (if applicable) to the 
subject. Information should be given in both oral and written form whenever possible and in the 
manner deemed appropriate by  the IRB or IEC.
The subject must be given ampl e opportuni ty to: (1) inquire about details of the study  and (2) 
decide whether or not to participate in the study. If the subject determines he or she will participate 
in the study, then the informed consent form and subject authorizat ion form (if applica ble) must be 
signed and dated by  the subject at the time of consent and prior to the subject entering into the 
study . The subject shoul d be instructed to si gn using their legal names, not nicknames, using blue 
or black ballpoint ink. The invest igator must also sign and date the informed consent form and 
subject authorizat ion (if applicable) at the time of consent and prior to subject entering into the 
study .
Once signed, the original informed consent form, subject authorization form (if applicable), and 
subject inform ation sheet (if applicable) will be stored in the invest igator’s site file. The 
investigator must document the date the subject signs the informed consent in the subject’s 
medical record. Copies of the signed informed consent form, the signed su bject authorization for m 
(if applicable), and subject informat ion sheet (if applicable) shall be given to the subject.
All revised informed consent forms must be reviewed and signed by relevant subjects in the same 
manner as the original informed consent. The date the revised consent was obtained should be 
recorded in the subject’s medical record, and the subject should receive a copy  of the revised 
inform ed consent form . 
Subjects who consented and provided a sample for DNA analysis can wit hdraw their cons ent and 
request di sposal  of a stored sam ple at any  time prior to analysis.
15.3 Subject Confidentiality
The sponsor and designees affirm and upho ld the principle of the subject’s right to protection 
against invasio n of privacy. Throughout this study , a subject’s source data will only be linked to 
the sponsor’s clinical trial database or documentation via a subject ident ification number. As 
permitted by all applicable laws and regulat ions, limited subject attributes, such as sex, age, or date 
of birth, an d subject init ials may be used to verify the subject and accuracy o f the subject’s unique 
ident ificat ion number.
To com ply with ICH Guidelines for GCP and to verify co mpliance with this protocol, the sponsor 
requi res the invest igator to permit the monitor or the sponsor’s designee, representatives fro m any 
regul atory  authori ty (eg, FDA, Medi cines and Heal thcare products Regul atory  Agency, 
Pharmaceut icals and Medical Devices Agency), the sponsor’s designated auditors, and the 
appropriate IRBs and IECs to review the subject’s original medical records (source data or 
docum ents), including, but not limited to, laboratory  test resul t reports, ECG reports, admissio n 
and discharge summaries for hospital admissio ns occurring during a subject’s study participation, 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 80of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALand autopsy  reports. Access to a subject’s original medical records requires the specific 
authori zation of the subject as part of the informed consent process (see Section 15.2) .
Copi es of  any subject source documents that are provided to the sponsor must have certain 
personally ident ifiable informat ion rem oved (ie, subject name, address, and other ident ifier fields 
not collected on the subject’s eCRF).
15.4 Publication, Dis closure, and Clinical Trial Registration Policy
15.4.1 Publication and Disclosure
The investigator is obliged to provide the sponsor with complete test results and all data derived by 
the invest igator from the study . During and after the study , only  the sponsor m ay make study  
inform ation available to other study  invest igators or to regulatory  agencies, except as required by  
law or regulation. Except as otherwise allo wable in the study site agreement, any public disclosure 
(including publicly accessible websites) r elated to the protocol or study  resul ts, other than study  
recrui tment m aterials and/or advertisements, is the sole responsibilit y of the sponsor.
The invest igator needs to obtain a prior written approval from the sponsor to publish any 
inform ation from thestudy  externally such as to a professio nal associ ation.
15.4.2 Clinical Trial Registration
In order to ensure that informat ion on clinical trials reaches the public in a timely manner and to 
comply with applicable laws, regulat ions and guidance, Takeda will, at a minimum register all 
intervent ional clinical tri als it sponsors anywhere in the worl d on ClinicalTrials.gov and/or other 
publicly  accessible websites before start of study , as defined in Takeda Policy/Standard . Takeda 
contact informat ion, along wit h inv estigator’s cit y, state (for Americas investigators), country, and 
recrui ting status will be registered and available for public viewing. 
For some registries, Takeda will assist callers in lo cating study  sites cl osest to thei r homes by 
provi ding the inves tigator nam e, address, and phone number to the callers request ing trial 
inform ation. Once subjects receive invest igator contact informat ion, they  may call  the si te 
requesting enrollment into the trial. The invest igative sites are encouraged to handle the t rial 
inquiries according to their established subject screening process. If the caller asks addit ional 
questions bey ond the topic of trial enro llment, they should be referred to the sponsor.
Any invest igator who objects to the sponsor providing this infor mation to callers must provide the 
sponsor with a written notice request ing that their informat ion not be listed on the registry  site. 
15.4.3 Clinical Trial Results Disclosure
Takeda will post the results of clinical trial son ClinicalTrials.gov and/or other pub licly accessible 
websites, as required by Takeda Policy/Standard, applicable laws and/or regulat ions.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 81of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL15.5 Insurance and Compensation for Injury
Each subject in the study  must be insured in accordance with the regulations applicable to the site 
where the subjec t is parti cipat ing. If a local underwriter is required, then the sponsor or sponsor’s 
designee will obtain clinical study  insurance against the risk o f injury to study  subjects. Refer to 
the study site agreement regarding the sponsor’s policy on subject co mpensat ion and treatment for 
injury . If the invest igator has questions regarding this policy, he or she should contact the sponsor 
or sponsor’s designee.
16.0 REFERENCES
1.Venara A, Neunlist M, Slim K, Barbieux J, Colas PA, Hamy A, et al. Postoperative ileus: 
Pathophy siology, incidence, and prevent ion. J Vi sc Surg 2016;153(6):439 -46.
2.Colorectal  Writing Group for the Scoap- Certain Collaborative, Ehlers AP, Simianu VV, 
Bastawrous AL, Billingham RP, Davidson GH, et al. Alvimopan use, outcom es, and costs: A 
report from the surgical care and outcomes assessment program comparative effect iveness 
research translat ion network collaborative. J Am Coll Surg 2016;222(5):870 -7.
3.Ahmed Ali U, Dunne T, Gurland B, Vogel JD, Kiran RP. Actual versus est imated length of 
stay after col orectal  surgery : which factors influence a deviat ion? Am J Surg 
2014;208(4):663 -9.
4.The FO, Bennink RJ, Ankum WM, Buist MR, Busch OR, Gouma DJ, et al. Intestinal 
handling -induced mast cell act ivation and inflammation in hum an postoperative ileus. Gut 
2008;57(1):33 -40.
5.Sloots CE, Ry kx A, Cool s M, Kerstens R, De Pauw M. Efficacy and safet y of prucal opride in 
patients wi th chroni c noncancer pain suffering from opio id-induced const ipation. Di g Dis Sci  
2010;55(10):2912 -21.
6.Gong J, Xie Z, Zhang T, Gu L, Yao W, Guo Z, et al. Rando mised clinical trial: prucalopride, a 
colonic pro -motility agent, reduces the duration of post -operative ileus after elect ive 
gastrointestinal surgery. Aliment Pharmaco l Ther 2016;43(7):778-89.
7.
Pedzi wiatr M, Ki sialeuski  M, Wierdak M, Stanek M, Natkaniec M, Matlok M, et al. Early 
implementation of Enhanced Recovery  After Surgery  (ERAS(R)) protocol -Com pliance 
improves outcomes: A prospective cohort study . Int J Surg 2015;21:75 -
81.
8.Keller DS, Bank witz B, Woconi sh D, Cham pagne BJ, Reyno lds HL, Jr., Stein SL, et al. 
Predi cting who will fail early  discharge after laparoscopic colorectal surgery  with an 
established enhanced recovery  pathway . Surg Endosc 2014;28(1):74- 9.
9.Grass F, Slieker J, Jurt J, K ummer A, Sola J, Hahnloser D, et al. Postoperative ileus in an 
enhanced recovery  pathway -a retrospective cohort study . Int J Col orectal  Dis 
2017;32(5):675 -81.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 82of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL10.Hussain Z, Lee YJ, Yang H, Jeong EJ, Sim JY, Park H. YH12852, a potent and highly select ive 
5-HT4 receptor agonist, significantly improves both upper and lower gastrointestinal motilit y 
in a guinea pig model of postoperative ileus. Neurogastroenterol Motil 2017;29(10):1 -
6.
11.Tsuchida Y, Hatao F, Fujisawa M, Murata T, Kaminishi M, Seto Y, et al. Neuronal  stimulat ion 
with 5-hydroxy tryptamine 4 receptor induces ant i-inflammatory act ions via alpha7nACh 
receptors on muscularis macrophages associated wit h postoperative ileus. Gut 
2011;60(5):638 -47.
12. Maca J, Peteja M, Reimer P, Jor O, Sedenkova V, Pa nackova L, et al. Surgical injury: 
comparing open surgery and laparoscopy by markers of tissue damage. Ther Clin Risk Manag 
2018;14:999 -1006.
13.Kenward H, Elliott J, Lee T, Pelligand L. Anti -nausea effects and pharmacokinet ics of 
ondansetron, maropitant and metoclopramide in a low- dose cisplat in model of nausea and 
vomiting in the dog: a blinded crossover study . BMC Vet Res 2017;13(1):244.
14.Luckey  A, Livingston E, Tache Y. Mechanisms and treatment of postoperative ileus. Arch 
Surg 2003;138(2):206 -14.
15.van Bree SH, Bemelman WA, Hollmann MW, Zwinderman AH, Matteoli G, El Temna S, et al. 
Ident ification of clinical outcome measures for recovery  of gastrointestinal mot ility in 
postoperative ileus. Ann Surg 2014;259(4):708-14.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 83of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALAppendix ASchedule of Study Procedures
Days
-21 to 
1 aBaseline/Day 1 
(Preinfusion)bDay 1 
(Postinfusion)Day 2 
to up 
Day 10Early 
Termination 
(ET)Days 16 to 24 
Interim 
Follow -up 
(14Days [±4 
Days] Post 
Last Dose) cDays 32 to 40 
Follow -up (30 days [±3 
days] Post Last Dose) 
(Phone Call)Days 92 to 100 
(90days [±7 days]) 
Post Last Dose
Final Follow -up 
(Phone Call)
Informed consent dX
Inclusion/exclusion 
criteriaX Xe
Demographics and medical 
historyX X
Medication history X X
Physical examination 
(including neurology 
examination) fX X X X X
Height, weight, and BMI X
Vital signs gX X X X X
Clinical assessment X X X
Concurrent medical 
proceduresX X X X X
Concomitant medications X X X X X X
ERP assessment X X h
Clinical laboratory 
evaluations iX X X X
Serum or urine pregnancy 
test (hCG) jX X X
12-lead ECG kX X X X X
Study  drug dosing lX X
SurgerymX
Plasma sample for 
TAK -954 PK nX X X
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 84of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALDays
-21 to 
1 aBaseline/Day 1 
(Preinfusion)bDay 1 
(Postinfusion)Day 2 
to up 
Day 10Early 
Termination 
(ET)Days 16 to 24 
Interim 
Follow -up 
(14Days [±4 
Days] Post 
Last Dose) cDays 32 to 40 
Follow -up (30 days [±3 
days] Post Last Dose) 
(Phone Call)Days 92 to 100 
(90days [±7 days]) 
Post Last Dose
Final Follow -up 
(Phone Call)
Serum sample for 
circulating biomarkers oX X X
Ready for discharge pX
Discharge papers written X
Discharge from hospital qX
EQ-5D rX X X
SF-12 rX X X
AE assessment sX X X X X X X
Abbreviations: AE, adverse event; BMI, body mass index; COVID -19, coronavirus disease 2019; ECG, electrocardiogram; EQ-5D, EuroQol 5-dimensional questionnaire ; ERP, 
enhanced recovery pathway; GI, gastrointestinal; HbA1c, glycosylated hemoglobin; PK, pharmacokinetics; SF
-12, 12-Item Short Form Health Survey; SOC, standard of care .
a All screening procedures need to be reviewed before randomization if done on Day 1. These screening procedures may be used as baseline parameters on Day 1.
bThe day of first study drug administration for the treatment period is Day 1. Baseline evaluations are defined as the assessm ent before first dose of study drug.
cDuring the COV ID-19 public health emergency, every attempt should be made to perform the follow -up visit at 14 days post last dose in clinic however, it may be conducted at the 
clinic or via phone call (eg, collection of AEs, concomitant medications, and monitoring) to extend flexibility to study subjects. In the case of a phone call follow -up, physical 
examination (including neurology examination), vital signs, or pregnancy test would not be collected; however, AEs will be as sessed, including a safety check on any emerg ing 
clinical sign or symptoms. Subjects may be requested to return to the site for further safety assessment, due to reported AEs , at the investigator’s discretion. The type of visit (whether 
clinic visit or phone call) must be recorded in the study record s.
d Informed consent will be signed before any study -specific procedures are performed. Informed consent may be performed in clinic or remotely using electronic signature where 
allowed by site institutional review boards/ethics committees.
eExcluded medi cations should be reassessed during the 24 hours prior to surgery.
f Physical examination includes a neurology examination. A targeted neurological examination looking for hypertonicity, reflexe s, and clonus will be performed by medically 
qualified personn el at screening, baseline (preinfusion on Day 1), on Days 2 and 5, on the last day of treatment, at the early termination vis it (as applicable), and at the safety follow -up 
visit (14 days post last dose). Physical examinations collected as SOC within 21 da ys of randomization may be used for study screening purposes. If physical examinations are 
collected as SOC on the day of surgery but before informed consent, they may be used for screening/baseline purposes as long as the results are assessed for eligibil ity before 
randomization.
g Vital signs will include blood pressure (systolic and diastolic) and pulse (beats per minute). Vital signs collected as SOC w ithin 21 days of randomization may be used for study 
screening purposes. If vital signs are collected as SOC on the day of surgery but before informed consent, they may be used for screening/baseline purposes as long as the results are 
assessed for eligibility before randomization. Vital signs will be collected at the following time points: screening, presurg ery before and at the end of infusion on Day 1, on Days 2 to 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 85of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL10 (ie, at the end of infusion in the morning and in the evening), and at the safety follow -up visit (on 14 days post last dose visit). Vital signs on day of surgery will be monitored 
according to SOC. Clinically abnormal vital signs will be captured as an AE as per NCI CTCAE v5.0. Subjects should have rested for at least 5 minutes before vital signs are assessed. 
When ECG, vital signs, and blood draw coincide at the same nominal time point, the sequence of procedures will be safety ECG, vital signs assessment, and blood draw.
hAssessment of ERP will be during the perioperative period on Day 1 and 2 only.
i Laboratory samples will be collected at screening, preinfusion Day 1 (Baseline) (note: it is not required that Day 1 laboratory assessments are reviewed before study drug 
administration) and Day 2. Results of clinical laboratory assessments collected as SOC within 21 days of randomization may be used for study screening purposes. If laboratory 
assessments are collected as SOC on the day of surgery but before informed consent, they may be used for screening/baseline purposes as long as the results are assessed for eligibility 
before randomization. In addition, liver test parameters (ie, ALT, AST, total bilirubin, alkaline phosphatase) will be tested on the last day of study dosing and early termination (as 
applicable). Clinical laboratory samples will be collected as per SOC and will not be duplicated. HbA1c to be collected at sc reening only (or collected as SOC within 30 d ays of 
informed consent may be used for screening purposes). Any clinically significant laboratory result will be captured as an AE as per NCI CTCAE v5.0.
j For women of childbearing potential. Beta hCG will be collected at screening , early termination (if applicable), and the follow -up visit (ie, 14 days post last dose).
k ECGs will be collected at screening; prior to and at the end of the infusion (+20 minutes) on Day 1; at the end of the 60 -minute IV infusion (+20 minutes) and approximately 2 hours 
(+20 minutes) after the start of the 60 -minute infusion on Day 2; at the end of the infusion (+20 minutes) on every other day of treatment (Days 4, 6, 8, and 10), and early termination 
(as applicable). Subjects should have rested in a supine or semisupine posit ion for at least 5 minutes before ECG assessment. The same position (either supine or semisupine) should 
be used for the same individual throughout the study. ECG assessments collected as SOC within 21 days of randomization may be used for study screening purposes. If an ECG is 
collected as SOC on the day of surgery but before informed consent, it may be used for screening/baseline purposes as long as the results are assessed for eligibility before 
randomization. When ECG, vital signs, and blood draw coinci de at the same nominal time point, the sequence of procedures will be safety ECG, vital signs assessment, and blood 
draw.
l On Day 1, the completion of the infusion should occur within 3 hours of the start of the surgery (induction of anesthesia). S ubseque nt doses (Days 2 to 10, if required) should be 
approximately 24 hours (±5 hours) from the start of the prior infusion. If a subsequent dose cannot be administered during th is window, it should be skipped.
mThe start and stop times of the surgery must be r ecorded. The start time of surgery is the start of general anesthesia.
n Subjects will have PK samples collected as follows: Day 1: Collect 1 sample prior (within 30 minutes) to the start of the inf usion, 1 sample at the end of the 60 -minute infusion (+10 
minutes), and another sample within the 1- to 3-hour window after the surgery, for a total of 3 samples. Day 2: Collect 1 sample prior (within 30 minutes) to the start of th e infusion, 
1sample at the end of the 60 -minute infusion (+10 minutes), and an add itional sample within the 3 -to 5-hour window after the end of the infusion, for a total of 3 samples; Day 3 up 
to Day 10 while on study drug: a trough (predose, within 30 minutes of the start of the infusion) sample obtained every other day starting on Da y 3. For the PK samples that correlate 
with the end of study drug infusion, the sample should always be collected from the arm opposite to the arm in which study dr ug is infused. When ECG, vital signs, and blood draw 
coincide at the same nominal time point , the sequence of procedures will be safety ECG, vital signs assessment, and blood draw.
o Subjects will have serum biomarker samples collected prior to and at the end of the infusion (+10 minutes) on Day 1 and after surgery; on Day 2, prior to and at 4 ho urs (+10 minutes) 
after the start of the infusion; on Day 3 up to Day 10, and a predose sample will be obtained every other day.
pReady for discharge is defined as the time when the subject presents effective intestinal transit (spontaneous bowel movement ), tolerates solids without clinically significant nausea 
and vomiting for 1 calendar day, has satisfactory pain control with oral analgesics, and is medically stable/free of complica tions. 
q Discharge cannot occur prior to the occurrence of the primary e ndpoints. If a subject meets the primary endpoint after midnight, discharge procedures can be completed the next day. 
This would not be considered a protocol deviation. If a subject meets the primary endpoint in the morning and is discharged later that day , this is considered a minor protocol 
deviation.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 86of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALr EQ-5D and SF-12 questionnaires will be conducted at baseline, last day of treatment, and at the Day 14 post last dose follow- up visit. At discharge, printed copy of SF -12 and EQ-5D 
(with pre -addressed enve lopes), will be provided to subjects as part of their discharge packages. If the Day 14 visit is done via phone follow -up, the study coordinator will remind 
subjects to complete the quality of life scales on the same day as the follow -up phone call and com pleted questionnaires will be mailed to the clinic.
s After informed consent, but before initiation of study drugs, only SAEs caused by a protocol -mandated intervention will be collected (eg, SAEs related to invasive procedures). All 
AEs and SAEs (treatmen t-emergent) will be collected from study drug start until 90 days post last dose. Serious and nonserious CV events (suspected i schemic heart disease, 
cerebrovascular accident [eg, transient ischemic attack and stroke], venous or arterial thromboembolic eve nts, or heart failure), SVT/arrhythmias and death will be collected.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 87of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALAppendix BResponsibilities of the Investigator
Clinical research studies sponsored by  the sponsor are subject to ICH GCP and all the applicable 
local laws and regulat ions. The responsibilit ies imposed on invest igators by  the FDA are 
summarized in the “Statement of Invest igator” (Form FDA 1572), whi ch must be com pleted and 
signed before the invest igator may participate in this study .
The invest igator agrees to assume the fo llowing responsibilit ies by signing a Form FDA 1572:
1.Conduct the study  in accordance wit h the protocol .
2.Personally conduct or supervise the staff who will assist in the protocol.
3.Ensure that study  related procedures, including study  specific (nonrouti ne/nonstandard panel) 
screening assessments are NOT performed on potent ial subjects, prior to the r eceipt of written 
approval  from relevant governing bodies/authorit ies.
4.Ensure that all co lleagues and emplo yees assist ing in the conduct of the study are informed of 
these obligat ions.
5.Secure prior approval o f the study and any changes by an appropriate IR B/IEC that conform to 
21 CFR Part 56, ICH, and local regulatory  requi rements.
6.Ensure that the IRB/IEC will be responsible for init ial review, continuing review, and approva l 
of the protocol. Promptly report to the IRB/IEC all changes in research act ivity and all 
anticipated risks to subjects. Make at least y early reports on the progress of the study  to the 
IRB/IEC, and issue a final report within 3 months of study  com pletion.
7.Ensure that requi rements for informed consent, as outlined, ICH and local regulat ions, are met.
8.Obtain valid informed consent from each subject who participates in the study , and docum ent 
the date of consent in the subject’s medical chart. Valid informed consent is the most current 
versio n approved by the IRB/IEC. Each informed consent form shoul d contain a subject 
authori zation sect ion that describes the uses and disclosures of a subject’s personal 
inform ation (including personal health informat ion) that will take place in connect ion wit h the 
study . If an informed consent form does not include such a subject authorization, then the 
investigator must obtain a separate subject authorization form from each subject.
9.Prepare and maintain adequate case histories of all persons entered into the study , incl uding 
eCRFs, hospital records, laboratory  resul ts, etc, and maintain these data for a minimum o f 
2years fo llowing notificat ion by the sponsor that all invest igations have been discont inued or 
that the regulatory  authori ty has approved the marketing applicat ion. The invest igator should 
contact and receive written approval fro m the sponsor before disposing o f any such 
docum ents.
10.Allow possible inspection and copying by the regulatory  authori ty of GCP -specified essent ial 
docum ents.
11.Maintain current records of the receipt, administratio n, and dispo sition of  sponsor -supplied 
drugs, and return all unused sponsor -
supplied drugs to the sponsor.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 88of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL12.Report adverse reactions to the sponsor prompt ly. In the event of an SAE, notify the sponsor 
within 24 hours.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 89of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALAppendix CElements of the Subject Informed Consent
In seeking informed consent, the fo llowing information shall be provided to each subject:
1.A statement that the study  involves research.
2.An explanat ion of the purposes of the research.
3.The expected duration of the subject’s participat ion.
4.A descript ion of the procedures to be fo llowed, including invasive procedures.
5.The i dentificat ion of any  procedures that are experimental.
6.The est imated number of subjects invo lved in the study .
7.A descript ion of the subject’s responsibilit ies.
8.A descript ion of the conduct of the study .
9.A statement describing the treatment(s) and the probabilit y for random  assignment to each 
treatm ent.
10.A descript ion of the possible side effects of the treatment that the subject may receive.
11.A descript ion of an y reasonably  foreseeable ri sks or di scomf orts to the subject and, when 
applicable, to an embry o, fetus, or nursing infant.
12.A descript ion of any  benefi ts to the subject or to others that reasonably  may be expected from  
the research. When there is no intende d clinical  benefi t to the subject, the subject should be 
made aware of this.
13.Disclosures o f appropriate alternat ive procedures or courses of treatment, if any, that might be 
advantageous to the subject and their important potent ial risks and benefits.
14.A statem ent describing the extent to which confident iality of records i dentifying the subject 
will be maintained, and a note of the possibilit y that regul atory  agencies, auditor(s), IRB/IEC, 
and the monitor may inspect the records. By  signing a written informe d consent form, the 
subject is authorizing such access.
15.For research invo lving more than minimal risk, an explanat ion as to whether any co mpensatio n 
and an explanat ion as to whether any medical treatments are available if injury occurs and, if so, 
what the y consist of or where further informat ion may be obtained.
16.The ant icipated prorated payment(s), if any, to the subject for participat ing in the study.
17.The ant icipated expenses, if any , to the subject for parti cipat ing in the study.
18.An explanat ion of whom t o contact for answers to pertinent questions about the research 
(invest igator), subject’s rights, and IRB/IEC and who m to contact i n the event of a 
research -related inj ury to the subject.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 90of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL19.A statement that participation is vo luntary, that refusal to partici pate will invo lve no penalt y or 
loss of benefits to which the subject otherwise is entit led, and that the subject may discont inue 
participat ion at any  time wi thout penal ty or loss of benefits to which the subject is otherwise 
entitled.
20.The consequences of a subject’s decisio n to wi thdraw from  the research and procedures for 
orderly terminat ion of part icipation by the subject.
21.A statement that the subject will be informed in a timely manner if informat ion beco mes 
available that may be relevant to the subject’s willingness to continue participat ion in the 
study .
22.A statement that results of pharmacogenomic analysis will not be disclosed to an individual, 
unless prevailing laws require the sponsor to do so.
23. The foreseeable circumstances or reasons under w hich the subject’s participat ion in the study  
may be terminated.
24.A wr itten subject authorization (eit her contained within the informed consent form or provided 
as a separate document) describing to the subject the contemplated and permissible uses and 
disclosures of the subject’s personal information (including personal health informat ion) for 
purposes of conduct ing the study. The subject authorizat ion must contain the fo llowing 
statements regarding the uses and disclosures of the subject’s personal informa tion:
a)that personal information (including personal healt h informat ion) may be processed by  or 
transferred to other parties in other countries for clinical research and safet y reporti ng 
purposes, including, without limitat ion, to the fo llowing: (1) Takeda, its affiliates, and 
licensing partners; (2) business partners assist ing Takeda, its affiliates, and licensing 
partners; (3) regulatory  agencies and other healt h authorities; and (4) IRBs/IECs;
b)it is possible that personal informat ion (including personal h ealth informat ion) may be 
processed and transferred to countries that do not have data protection laws that offer 
subjects the same level o f protecti on as the data protection laws wit hin this country; 
however, Takeda will make every  effort to keep y our per sonal inform ation confident ial, 
and y our name will not be di sclosed outsi de the clinic unless required by law;
c)that personal information (including personal healt h informat ion) may be added to 
Takeda’s research databases for purposes of developing a better understanding of the 
safet y and effect iveness o f the study  drug(s), studying other therapies for patients, 
developing a better understanding of disease, and improving the efficiency of future 
clinical studies;
d)that subjects agree not to restrict the use a nd disclo sure of their personal informat ion 
(including personal healt h informat ion) upon withdrawal fro m the study  to the extent that 
the restricted use or disclosure of such informat ion may  impact the scient ific integrity of 
the research; and
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 91of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALe)that the subject’s i dentity will remain confident ial in the event that study  resul ts are 
published.
25.Female subjects of childbearing potential (eg, nonsterilized, premenopausal female subjects) 
who are sexually  active m ust use highly  effect ive contraception (as defined in the informed 
consent) from screening throughout the duration of the study , and f or 30 day s after the l ast 
dose. If a subject is found to be pregnant during study, study drug will be discont inued and the 
investigator will offer the subject the cho ice to receive unblinded treatment information.
26.Male subjects must use highly effect ive contraceptio n (as defined in the informed consent) 
from signing the informed consent throughout the duration of the study , and for 30 days after
the last dose. If the partner or wife of the subject is found to be pregnant during the study, the 
investigator will offer the subject the cho ice to receive unblinded treatment information.
27.A statem ent that clinical trial informat ion fro m this trial will be publicly disclo sed in a pub licly 
accessible website, such as ClinicalTrials.gov.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 92of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALAppendix DInvestigator Consent to Use of Personal Information
Takeda will co llect and retain personal information of invest igator, including his or her name, 
address, and other personally identifiable informat ion. In addit ion, invest igator’s personal 
inform ation may be transferred to other parties located in countries throughout the world (eg, the 
United Kingdom, United States, and Japan), including the following:
Takeda, its affiliates, and licensing partners.
Business partners assist ing Takeda, its affiliates, and licensing partners.
Regulatory  agencies and other health authorit ies.
IRBs and IECs.
Invest igator’s personal informat ion may be retained, processed, and transfe rred by  Takeda and 
these other parties for research purposes including the fo llowing:
Assessment of the suitabilit y of invest igator for the study  and/or other clinical studies.
Management, monitoring, inspect ion, and audit of the study .
Analysis, review, a nd verificat ion of the study  results.
Safety reporti ng and pharmacovigilance relat ing to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies relat ing to other medications used in other clinical studies that may contain 
the sam e chemical com pound present in the study  drug.
Inspect ions and invest igations by regul atory  authorit ies relat ing to the study.
Self-inspect ion and internal audit within Takeda, its affiliates, and licensing partners.
Archiving and audit of study  records.
Posting investigator site contact informat ion, study details and results on public ly accessible 
clinical trial registries, databases, and websites.
Invest igator’s personal informat ion may be transferred to other countries that do not have data 
protecti on laws that offer the same level of protection as data protection laws in invest igato r’s own 
country .
Invest igator acknowledges and consents to the use of his or her personal information by Takeda 
and other parties for the purposes described above.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 93of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALAppendix EProtocol History
Date Amendment Number Amendment T ype Region
23 March 2021 Amendment 5 Substantial Global
09 July  2019 Amendment 4 Substantial Global
13 May  2019 Amendment 3 Substantial Local (Germany)
23 April 2019 Amendment 2 Nonsubstantial Local (Belgium)
19 December 2018 Amendment 1 Not applicable Global
15 October 2018 Initial protocol Not applicable Global
Rationale for Amendment 4
The primary  reason for thi s amendment is to produce 1 common international protocol by 
incorporating individual country  amendments (Germany’s Bundesinst itut für Arzneimittel und 
Medizinprodukte [BfArM] and Belgium’s Federal Agency for Medicines and Health Products) 
containing responses to their regulatory  reviews. In addit ion, the am endment contains changes to 
address operational issues and an u pdated list of prohibited medicines as a consequence of new 
data supporting the absence of direct evidence suggesting a relationship between select ive 5 -HT 4
agonist and serotonin syndrome.
Changes in Amendment 4
1.Clarificat ion of the end of the surgery .
2.Correction of the collect ion of a peak nausea severit y score.
3.Clarificat ion of the maximum dose that will be used for this study.
4.Addit ion of the just ificat ion for a m aximum  dose of 1.0 m g TAK -954.
5.Added definit ion for the end of the study .
6.Deleted “subject’s legally acceptable representative”.
7.Clarificat ion of who can review an electrocardiogram (ECG) for inclusion into the study.
8.Revised the timeframe for excluded medicat ions.
9.Clarificat ion of laxative use.
10.Removal of medicat ions associated with serotonin sy ndrome.
11.Clarificat ion of drug dosing in relation to surgery  delays.
12.Clarificat ion of the use of the interactive response techno logy (IRT).
13.Clarificat ion of the procedure for clinically significant physical examinat ion changes.
14.Addit ion of the collect ion ofapproximate l ength of bowel  removed during surgery .
15.Clarificat ion of the clinical assessments.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 94of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIAL16.Revised highly effective forms of contraception.
17.Clarificat ion of ECG procedures.
18.Clarificat ion of the qualit y of life assessment.
19.Clarificat ion of specific adverse events (AEs) related to cardiovascular (CV) events. 
20.Correcti on of  the m anagement of QT prolongat ion.
21.Clarificat ion of the procedure for suspected serotonin syndrome.
22.Correcti on of  action concerning study  drug.
23.Correcti on of  the m embers of the internal monitoring co mmit tee (IMC).
24.Correcti on of  the analysis of the primary  endpoint.
25.Addit ion of a pregnancy test at the Days 16 to 24 follow -up visit.
26.Correcti on and clarification o f laboratory  sample collect ion.
27.Clarificat ion of pharmacokinet ic (PK) sample collection.
28.Correcti on of  plasma and serum  biomarker sam ple collect ion.
29.Correcti on of  ERP assessments.
Rationale for Amendment 3
The primary  reason for thi s amendment is in response to the Bundesinst itut für Arzneimittel und 
Medizinprodukte responses.
Chan ges in Amendment 3:
1.Added definit ion for the end of the study .
2.Deleted “subject’s legally acceptable representative”.
3.Revised the timeframe for excluded medicat ions.
4.Revised highly effective forms of contraception.
5.Added a pregnancy  test at the Day s 16 to 24 follo w-up visit.
Rationale for Amendment 2
The primary  reason for thi s amendment is in response to the Federal Agency  for Medicines and 
Health Products.
Changes in Amendment 2
1.Clarificat ion of the maximum dose that will be used for this study.
2.Addit ion of the j ustificat ion for a m aximum  dose of 1.0 m g TAK -954.
3.Addit ion of a pregnancy test at the Days 16 to 24 follow -up visit.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -954
Study No. TAK -954-2004 Page 95of 95
Protocol Incorporating Amendment No. 5 23 March 2021
CONFIDENTIALRationale for Amendment 1
The primary  reason for thi s amendment is clarification fo llowing init ial discussio n with 
investigators.
Changes in Amendment 1
1.Revisio n and addit ion of exploratory  objectives.
2.Clarificat ion of primary  endpoint.
3.Addit ion and clarification o f secondary  endpoints.
4.Addit ion and clarification o f exploratory  endpoints.
5.Deletion and clarificat ion of core enhanced recovery pathway  (ERP).
6.Removal of subject daily diary  and clarificat ion of bowel  movement.
7.Revisio n of exclusio n criteria regarding glycoso lated hemoglobin requirements and addit ion of 
exclusio n criteria regarding radiat ion.
8.Revised and added criterion fo r discont inuat ion or wi thdrawal  of a subject regarding study  
drug dosing.
9.Addit ional instructi ons rel ated to timing of dosing and the surgery .
10.Addit ion and clarification o f vital sign m easurements.
11.Revisio n of POGD assessment.
12.Added section for documentati on of  concurrent m edical procedures.
13.Clarificat ion of conco mitant m edicat ions.
14.Clarificat ion of concurrent medical condit ions.
15.Revised pregnancy  test to all ow for serum  or urine and added glycosylated hemoglo bin 
(HbA1c) to the clinical laboratory  table.
16.Clarificat ion of ECG procedures.
17.Clarificat ion of PK sampling.
18.Added a qualit y of life assessment at hospital discharge.
19.Correcti on of  SAE or AESI reporti ng to the safet y database.
20.Addit ion of Baseline co lumn to Schedule of Assessments table and corrections throughout. 
21.Correcti on of  the docum entati on of  clinically  significant changes for physical examinat ions.
22.Added laxat ives to the excluded medicat ions list.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use